

JOSEP CARRERAS LEUKAEMIA RESEARCH INSTITUTE

SCIENTIFIC PRODUCTION

2011-2015

2011

1. **RIBERA JM.** Hope for very elderly patients with diffuse large B-cell lymphoma. *Lancet Oncol.* 2011; 12:412-3. **IF: 22,589 (JCR 2014).** Times cited: 1. Q1
2. **RIBERA JM.** Advances in acute lymphoblastic leukemia in adults. *Curr Opin Oncol.* 2011; 23: 692-9. **IF: 4,101 (JCR 2014).** Times cited: 13. Q1
3. **RIBERA JM.** Allogeneic stem cell transplantation for adult acute lymphoblastic leukemia: when and how. *Haematologica.* 2011; 96:1083-6. **IF: 6,424 (JCR 2014).** Times cited: 8. Q1
4. **XICOY B, RIBERA JM, MIRALLES P, LA CRUZ J, ORIOL A, VALENCIA E, MORGADES M, MAHILLO B, DE LA TORRE J, TÉLLEZ MJ, BRUNET S, ESTEVE J, HOELZER D.** Comparison of CHOP treatment with specific short-intensive chemotherapy in AIDS-related Burkitt's lymphoma or leukemia. *Med Clin (Barc).* 2011;136: 323-8. **IF: 1,385 (JCR 2014).** Times cited: 6. Q2
5. **MOTLLÓ C, MANUEL SANCHO J, GARCÍA O, GRANADA I, MILLÁ F, RIBERA JM.** Leucemia aguda secundaria: estudio de 23 pacientes. *Med Clin (Barc).* 2011;137: 449-52. **IF: 1,385 (JCR 2014).** Times cited: 0. Q2
6. **MOTLLÓ C, FERRÀ C, LÓPEZ L, MORGADES M, BATLLE M, RIBERA JM.** Tratamiento de rescate con infliximab de la enfermedad del injerto contra el huésped refractaria. *Med Clin (Barc).* 2011;137:115-8. **IF: 1,385 (JCR 2014).** Times cited: 3. Q2
7. **E COBO, J CORTES, JM RIBERA, F CARDELLACH, A SELVA-O'CALLAGHAN, B KOSTOV, L GARCÍA, L CIRUGEDA, D ALTMAN, JA GONZÁLEZ, JA SANCHEZ, F MIRAS, A URRUTIA, V FONOLLOSA, C REY-JOLY, M VILARDELL.** Effect of reporting guidelines provided at the reviewing phase on final manuscript quality: a randomized trial. *Br Med J* 2011 Nov 22; 343:d6783. doi: 10.1136/bmj.d6783. **IF: 14,093 (JCR 2014).** Times cited: 68

2012

1. **RIBERA JM, MORGADES M, GONZÁLEZ-BARCA E, MIRALLES P, LÓPEZ-GUILLERMO A, GARDELLA S, LÓPEZ A, ABELLA E, GARCÍA M, NAVARRO JT, FELIU E.** Long-term follow-up of patients with HIV-related diffuse large B-cell lymphomas treated in a phase II study with rituximab and CHOP. *Br J Haematol.* 2012; 157: 637-9. **IF: 4,942 (JCR 2014).** Times cited: 5. Q1
2. **JM RIBERA, O GARCÍA, P MONTESINOS, S BRUNET, E ABELLA, M BARRIOS, J GONZÁLEZ-CAMPOS, P BRAVO, ML AMIGO, JM HERNÁNDEZ-RIVAS.** Treatment of young patients with

- Philadelphia chromosome-positive acute lymphoblastic leukaemia using increased dose of imatinib and deintensified chemotherapy before allogeneic stem cell transplantation. *Br J Haematol* 2012; 159: 78-81. **IF: 4,942 (JCR 2014)**. Times cited: 9. Q1
3. **SANCHO JM, MORGADES M, GRIFOLS JR, JUNCÀ J, GUARDIA R, VIVES S, FERRÀ C, BATLLE M, ESTER A, GALLARDO D, MILLÀ F, FELIU E, RIBERA JM**. Predictive factors for poor peripheral blood stem cell mobilization and peak CD34+ cell count to guide pre-emptive or immediate rescue mobilization. *Cytotherapy* 2012; 14: 823-829. **IF: 3,055 (JCR 2014)**. Times cited: 10. Q2
 4. **VIVES S, SANCHO JM, ALMAZÁN F, JUNCÀ J, GRIFOLS JR, RIBERA JM**. Plerixafor plus G-CSF in combination with chemotherapy for stem cell mobilization in a pediatric patient with Ewing's sarcoma. *J Clin Apher.* 2012 May 7. doi: 10.1002/jca.21234. **IF: 2,265 (JCR 2014)**. Times cited: 2 Q 4.
 5. **M SAGUES, JM SANCHO, D SERRANO, P BALSALOBRE, J GAYOSO, M MORGADES, E CONDE, A IRIONDO, R VARELA, L ESCODA, B XICOY, I ESPIGADO, P FERNÁNDEZ-ABELLÁN, JL DÍEZ, JM RIBERA**. Comparación de dos estrategias iniciales de movilización de progenitores hematopoyéticos de sangre periférica para trasplante autogénico en pacientes con linfomas e infección por el virus de la inmunodeficiencia humana. *Med Clín (Barc)* 2012; 139: 192-196. **IF: 1,399 (JCR 2014)**. Times cited: 0. Q2
 6. **JIMÉNEZ MJ, FERRÀ C, FELIU E, RIBERA JM**. Resultados de un proceso de capacitación del personal implicado en un programa clínico de trasplante de progenitores hematopoyéticos. *Med Clin (Barc)*. 2012; 138:589-90. **IF: 1,399 (JCR 2014)**. Times cited: 0. Q2
 7. **JM RIBERA**. Improvements in the treatment of T-cell acute lymphoblastic leukemia in children. *Med Clín (Barc)* 2012; 139: 161-162. **IF: 1,399 (JCR 2014)**. Times cited: 0. Q2
 8. **C FERRA, JM RIBERA**. Prognosis of the hematologic patients admitted to an Intensive Care Unit. *Med Clin (Barc)* 2012; 139: 631-633. **IF: 1,399 (JCR 2014)**. Times cited: 0. Q2
 9. **C FERRÀ, A LACOMA, O GARCÍA, P MARCOS, J DOMÍNGUEZ, JM RIBERA**. Relación entre los valores séricos de procalcitonina y las complicaciones y supervivencia de pacientes con hemopatías malignas ingresados en una Unidad de Vigilancia Intensiva. *Med Clín (Barc)*. 2012; 138: 385-388. **IF: 1,399 (JCR 2014)**. Times cited: 3. Q2
 10. **PÉREZ-MONTAÑA A, SANCHO JM, MATE JL, RIBERA JM**. Association over time of Hodgkin lymphoma and non-Hodgkin lymphoma: study of 6 patients in one single center. *Med Clin (Barc)*. 2012 . **IF: 1,399 (JCR 2014)**. Times cited: 1. Q2
 11. **SAGÜÉS M, NAVARRO JT, RIBERA JM, MILLÀ F**. Linfoma de Hodgkin en paciente con Enfermedad de Crohn tratada con azatioprina y anticuerpos antifactor de necrosis tumoral alfa. *Medicina Clínica (Barc)* 2012; 138: 366-367. **IF: 1,399 (2012)**. Times cited: 0. Q2

12. **ZAMORA L, XANDRI M, GARCIA O, MARCÉ S, XICOY B, GRANADA I, NAVARRO JT, MILLÁ F.** Association of JAK2 mutation status and cytogenetic abnormalities at diagnosis in Myeloproliferative Neoplasms and Myelodysplastic/Myeloproliferative Neoplasms. *Am J Clin Pathol* 2012;137:677-678. **IF: 2,881 (JCR 2014).** Times cited: 4. Q2
13. MARTÍN-ANTONIO B, ALVAREZ LADERAS I, CARDESA R, MÁRQUEZ MALAVER F, BAEZ A, CARMONA M, FALANTES J, SUAREZ-LLEDO M, FERNÁNDEZ AVILÉS F, MARTÍNEZ C, ROVIRA M, ESPIGADO I, **URBANO-ISPIZUA A.** A constitutional variant in the transcription factor EP300 strongly influences the clinical outcome of patients submitted to allo-SCT. *Bone marrow transplant* 2012 47 (9): 1206-11. **IF: 3,541 (JCR 2014).** Times cited: 2. Q2
14. **URBANO-ISPIZUA A, BALDOMERO H, GRATWOHL A.** Hematopoietic stem cell transplantation in Europe. Differences between Eastern and Western countries. *Hematology.* 2012 Apr;17 Suppl 1:S192-4. **IF: 1,393 (JCR 2014).** Times cited: 1. Q4
15. **RIBERA, JOSEP-MARIA; GARCIA, OLGA; FERNANDEZ-ABELLAN, PASCUAL; LAVILLA, ESPERANZA; BERNAL, MARIA-TERESA; GONZALEZ-CAMPOS, JOSE; BRUNET, SALUT; MONTESERIN, MARIA-CARMEN; MONTESINOS, PAU; SARRA, JOSEP; CALBACHO, MARIA; ALVAREZ-LARRAN, ALBERTO; TORMO, MAR; ORIOL, ALBERT.** Lack of negative impact of Philadelphia chromosome in older patients with acute lymphoblastic leukaemia in the tyrosine kinase inhibitor era: comparison of two prospective parallel protocols. *BRITISH JOURNAL OF HAEMATOLOGY.* 2012. 159 (4) 485-488; 10.1111/bjh.12043. **IF: 4,942 (JCR 2014).** Times Cited: 5. Q1
16. SCHANZ, JULIE; TUECHLER, HEINZ; **SOLE, FRANCESC; MALLO, MAR; LUNO, ELISA; CERVERA, JOSE; GRANADA, ISABEL; HILDEBRANDT, BARBARA; SLOVAK, MARILYN L.; OHYASHIKI, KAZUMA; STEIDL, CHRISTIAN; FONATSCH, CHRISTA; PFEILSTOECKER, MICHAEL; NOESSLINGER, THOMAS; VALENT, PETER; GIAGOUNIDIS, ARISTOTELES; AUL, CARLO; LUEBBERT, MICHAEL; STAUDER, REINHARD; KRIEGER, OTTO; GARCIA-MANERO, GUILLERMO; FADERL, STEFAN; PIERCE, SHERRY; LE BEAU, MICHELLE M.; BENNETT, JOHN M.; GREENBERG, PETER; GERMING, ULRICH; HAASE, DETLEF.** New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge. *JOURNAL OF CLINICAL ONCOLOGY.* 2012. 30 8 820 829 10.1200/JCO.2011.35.6394. **IF: 18,038 (JCR 2014).** Times Cited: 174. Q1

2013

1. VALCÁRCEL D, **ADEMÁ V, SOLE F, ORTEGA M, NOMDEDEU B, SANZ GF, LUÑO E, CAÑIZO C, DE LA SERNA J, ARDAÑAZ M, MARCO V, COLLADO R, GRAU J, MONTORO J, MALLO M, VALLESPÍ T:** Complex, Not Monosomal, Karyotype is the Cytogenetic Marker of Poorest Prognosis in patients with myelodysplastic syndrome. *J Clin Oncol.* 2013: 31(7):916-922. **IF: 17,960 (JCR 2014).** Times cited: 21. Q1
2. **MARCÉ S, ZAMORA L, CABEZÓN M, XICOY B, BOQUÉ C, DOMÍNGUEZ D, RIBERA J, FERNÁNDEZ C, RODRÍGUEZ LL, PORTAL I, PLENSA E, VELEZ P, MEDINA J, GRAU J, XANDRI M, NAVARRO JT, FERNÁNDEZ DE SEVILLA A, RIBERA JM, FELIU E, MILLÁ F.** Frequency of *ABL* gene mutations in Chronic Myeloid Leukemia patients resistant to Imatinib and results of treatment shift to second-generation tyrosine kinase inhibitors. *Med Clin* 2013; 141:95-99. **IF: 1,252 (JCR 2014).** Timed cited: 3. Q2.

3. **PALOMO L, ZAMORA L, XICOY B, CORTÉS M, CABEZÓN M, TORRENT A, FELIU E, MILLÁ F, RIBERA JM.** Chronic myelomonocytic leukaemia diagnosed by means of mutational analysis in a patient with persistent monocytosis and tuberculosis. *Leukemia & Lymphoma* 2013; 54:2297-2298. **IF: 2,605 (JCR 2014).** Times cited: 0. Q2.

4. **PUIGGROS A, DELGADO A, RODRIGUEZ-VICENTE A, COLLADO R, AVENTÍN A, LUÑO E, GRAU J, HERNANDEZ JA, MARUGÁN I, ARDANAZ M, GONZÁLEZ T, VALIENTE A, OSMA M, CALASANZ MJ, SALIDO M, IVARS D, SANZO C, RUIZ-XIVILLÉ N, CARRIÓ A, GONZÁLEZ M, BENET I, ORTEGA M, SANTACRUZ R, FERNÁNDEZ E, ORTUÑO F, ABRISQUETA P, OLAVARRÍA E, OLIVEIRA AC, MARCO MJ, ARRANZ E, CERVERA J, BATLLE A, ABELLA E, FERRÁ C, TEROL MJ, MUÑOZ C, FERRER A, LOSCERTALES J, BOSCH F, CARBONELL F, SOLÉ F, HERNÁNDEZ JM, ESPINET B,** on behalf of Grupo Cooperativo Español de Citogenética Hematológica (GCECGH) and Grupo Español de Leucemia Linfática Crónica (GELLC) (2013): Biallelic losses of 13q do not confer a poorer outcome in chronic lymphocytic leukaemia: analysis of 627 patients with isolated 13q deletion. *British Journal of Haematology* 163 (1):47-54. **IF: 4,959 (JCR 2014).** PMID: 23869550 Times cited: 5. Q1

5. **ADEMÀ V, HERNÁNDEZ JM, ABÁIGAR M, LUMBRERAS E, SUCH E, CALULL A, DOMINGUEZ E, ARENILLAS L, MALLO M, CERVERA J, MARUGÁN I, TORMO M, GARCÍA F, GONZÁLEZ T, LUÑO E, SANZO C, MARTÍN ML, FERNÁNDEZ GUIJARRO M, COSTA D, BLÁZQUEZ, BEATRIZ BARREÑA B, MARCO F, BATLLE A, BUÑO I, MARTÍNEZ-LAPERCHE C, NORIEGA V, COLLADO R, IVARS D, CARBONELL F, VALLCORBA I, MELERO J, DELGADO E, VARGAS MT, GRAU J, SALIDO M, ESPINET B, MELERO C, FLORENSA L, PEDRO C, SOLÉ F** (2013): Application of FISH 7q in 750 myelodysplastic syndromes patients without monosomy 7 or 7q deletion by conventional G-banding cytogenetics. Does -7/7q- detection by FISH have prognostic value? *Leukemia Research* 37(4):416-421. **IF: 2,692 (JCR 2014)** PMID: 23337401. Times cited: 6. Q3

6. **MALLO M, DEL REY M, IBAÑEZ M, CALASANZ MJ, LARRAYOZ MJ, ARENILLAS A, PEDRO C, JEREZ A, MACIEJEWSKKI J, COSTA D, NOMDEDEU M, DIEZ-CAMPELO M, LUMBRERAS E, GONZALEZ-MARTINEZ T, MARRUGAN I, SUCH E, CERVERA J, CIGUDOSA JC, FLORENSA L, HERNANDEZ JM, SOLE F** (2013): Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations. *British Journal of Haematology* 162(1):74-86. **IF: 4,959 (JCR 2014).** PMID: 23614682 Times cited: 19. Q1

7. **SÁNCHEZ-CASTRO J, MARCO-BETÉS V, GÓMEZ-ARBONÉS X, ARENILLAS L, VALCARCEL D, VALLESPÍ T, COSTA D, NOMDEDEU B, JIMENEZ MJ, GRANADA I, GRAU J, ARDANA MT, DE LA SERNA J, CARBONELL F, CERVERA J, SIERRA A, LUÑO E, CERVERO CJ, FALANTES J, CALASANZ MJ, GONZÁLEZ-PORRÁS JR, BAILÉN A, AMIGO ML, SANZ G, SOLÉ F** (2013): Characterization and prognostic implication of 17 chromosome abnormalities in myelodysplastic syndrome. *Leukemia Research* 37(7):769-776. **IF: 2,692 (JCR 2014).** PMID 23639672. Times cited: 2. Q3

8. **COSTA D, MUÑOZ C, CARRIO A, NOMDEDEU M, CALVO X, SOLÉ F, LUÑO E, CERVERA J, VALLESPÍ T, BERNEAGA D, GOMEZ C, ARIAS A, SUCH E, SANZ GF, GRAU J, ISUNZA A, CALASANZ MJ, ARDANAZ MT, HERNÁNDEZ JM, AZACET G, ALVAREZ S, SANCHEZ J, MARTIN ML, BARGAY J, GOMEZ V, CERVERO CJ, ALLEGUE MJ, COLLADO R, CAMPO E, NOMDEDEU B** (2013): Reciprocal

- translocations in Myelodysplastic syndromes and chronic myelomonocytic leukaemias: review of 5.654 patients with an evaluable karyotype. *Genes Chromosomes and Cancer* 52(8):753-763 **IF: 3,836 (JCR 2014)**. PMID: 23686965. Times cited: 1. Q1
9. NADAL R, FERNÁNDEZ A, SALIDO M, LORENTE JA, RODRÍGUEZ-RIVERA M, DELGADO-RODRÍGUEZ M, MACIÀ M, COROMINAS JM, SÁNCHEZ-ROVIRA P, **SOLÉ F**, SERRANO MJ (2013): CD133 expression in circulating tumor cells from breast cancer patients: Potential role in breast cancer subtypes and resistance to chemotherapy. *International Journal of Cancer* 133(10):2398-2407. **IF 5,007 (JCR 2014)**. PMID 23661576. Times cited: 21. Q1
 10. SCHANZ J, TÜCHLER H, **SOLÉ F**, **MALLO M**, LUÑO E, CERVERA J, **GRAU J**, HILDEBRANDT B, SLOVAK ML, OHYASHIKI K, STEIDL C, FONATSCH C, PFEILSTÖCKER P, NÖSSLINGER T, VALENT P, GIAGOUNIDIS A, AUL A, LÜBBERT M, STAUDER R, KRIEGER O, LE BEAU MM, BENNETT JM, GREENBERG P, GERMING U, HAASE D (2013): Monosomal karyotype in MDS: What determines the poor prognosis? *Leukemia* 27(10):1988-1995. **IF: 9,379 (JCR 2014)**. PMID:23787396. Times cited: 10. Q1
 11. ARENILLAS L, **MALLO M**, RAMOS F, GUINTA K, BARRAGÁN E, LUMBRERAS E, LARRÁYOZ MJ, DE PAZ R, TORMO M, ABAIGAR M, PEDRO C, CERVERA J, SUCH E, CALASANZ MJ, DÍEZ-CAMPELO M, SANZ GF, HERNÁNDEZ JM, LUÑO E, SAUMELL S, MACIEJEWSKI J, FLORENSA L, **SOLÉ F** (2013): Single nucleotide polymorphism array karyotyping, a diagnostic and prognostic tool in primary myelodysplastic syndromes with unsuccessful conventional cytogenetic testing. *Genes Chromosomes and Cancer*. **IF: 3,836 (JCR 2014)**. Times cited: 4. Q1
 12. BARTA SK, XUE X, WANG D, TAMARI R, LEE JY, MOUNIER N, KAPLAN LD, **RIBERA JM**, SPINA M, TIRELLI U, WEISS R, GALICIER L, BOUE F, WILSON WH, WYEN C, **ORIOL A**, **NAVARRO JT**, DUNLEAVY K, LITTLE RF, RATNER L, GARCIA O, **MORGADES M**, REMICK SC, NOY A, SPARANO JA. Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1,546 patients. *Blood*. 2013 Sep 6. PubMed PMID: 24014242. **IF: 9,775 (JCR 2014)**. Times cited: 23. Q1
 13. **NAVARRO JT**, **BAPTISTA MJ**, MORGADES M, TURAL C, **MILLÁ F**, **FELIU E**, **RIBERA JM**. Neoplasms and infections as the main causes of death in patients in complete response to HIV-related non-Hodgkin lymphoma in the combination antiretroviral therapy era: a study out of a series of 146 patients. *Br J Haematol*. 2013 Jul;162(2):289-91. doi: 10.1111/bjh.12355. Epub 2013 Apr 25. PubMed PMID: 23617413. **IF: 4,959 (JCR 2014)**. Times cited: 1
 14. **RIBERA JM**, GARCÍA O, GRANDE C, ESTEVE J, **ORIOL A**, BERGUA J, GONZÁLEZ-CAMPOS J, VALLLOVERA F, TORMO M, HERNÁNDEZ-RIVAS JM, GARCÍA D, BRUNET S, ALONSO N, BARBA P, MIRALLES P, LLORENTE A, MONTESINOS P, MORENO MJ, HERNÁNDEZ-RIVAS JÁ, BERNAL T. Dose-intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status: final results of a phase 2 study (Burkimab). *Cancer*. 2013 May 1;119(9):1660-8. doi: 10.1002/cncr.27918. PubMed PMID: 23361927. **IF: 4,901 (JCR 2014)**. Times cited: 10
 15. TORRENT A, **NAVARRO JT**, ANDREO FC, **RIBERA JM**. [Sarcoidosis-like reaction after treatment with doxorubicin, bleomycin, vinblastine and dacarbazine in a patient with Hodgkin's

- lymphoma]. *Med Clin (Barc)*. 2013 Aug 4; 141(3):134-5. doi: 10.1016/j.medcli.2012.11.019. Epub 2013 Jan 18. Spanish. PubMed PMID: 23332624. **IF: 1,252 (JCR 2014)**. Times cited: 0. Q2
16. JUNCA J, **GRANADA I, RODRIGUEZ-HERNÁNDEZ I, MILLÁ F**. CD11b expression correlates with monosomal karyotype predictive an extremely poor prognosis in cytogenetically unfavorable acute myeloid leukemia. *Leukemia Research* 2013 Aug. 37 (8): 859-860. **IF: 2,692 (JCR 2014)**. Times cited: 1. Q3
 17. **FERNÁNDEZ DE LARREA C, MARTÍN-ANTONIO B, CIBEIRA MT, NAVARRO A, TOVAR N, DÍAZ T, ROSIÑOL L, MONZÓ M, URBANO-ISPIZUA A, BLADÉ J**. Impact of global and gene-specific DNA methylation pattern in relapsed multiple myeloma patients treated with bortezomib. *Leuk Res*. 2013;37(6): 641-6. **I.F: 2,692 (JCR 2014)**. Times cited: 5. Q3
 18. ISERN J, MARTÍN-ANTONIO B, GHAZANFARI R, MARTÍN AM, LÓPEZ JA, DEL TORO R, SÁNCHEZ-AGUILERA A, ARRANZ L, MARTÍN-PÉREZ D, SUÁREZ-LLEDÓ M, MARÍN P, VAN PEL M, FIBBE WE, VÁZQUEZ J, SCHEDING S, **URBANO-ISPIZÚA A, MÉNDEZ-FERRER S**. Self-Renewing human bone marrow Mesospheres Promote Hematopoietic Stem Cell Expansion. *Cell Rep*. 2013; 30: 3(5): 1714-24. **I.F: 7,207 (JCR 2014)**. Times cited: 26. Q1
 19. ARRANZ L, **URBANO-ISPIZÚA A, MÉNDEZ-FERRER S**. Mitochondria underlie different metabolism of hematopoietic stem and progenitor cells. *Haematologica*. 2013; 98(7):993-5. **I.F: 5,868 (JCR 2014)**. Times cited: 1. Q1
 20. R. RODRIGUEZ, J. TORNÍN, C. SUÁREZ, R. RUBIO, M. ROSU-MYLES, A. WILLIAMS, C. YAUK, JM. FUNES, C. BOSHOFF, **P. MENENDEZ**. Expression of FUS-CHOP fusion protein in immortalized/transformed human mesenchymal stromal/stem cells drives mixoid liposarcoma formation. *STEM CELLS* 2013; 31:2061-72. **IF: 7,133 (JCR 2014)**. Times cited: 9. Q1
 21. P.J. REAL, O. NAVARRO-MONTERO, V. AYLLÓN, V. RAMOS-MEJÍA, **C. BUENO, P. MENENDEZ**. The role of RUNX1 isoforms in hematopoietic commitment from human pluripotent stem cells. *BLOOD* 2013; 121:5250-5252. **IF: 9,775 (JCR 2014)**. Times cited: 1. Q1
 22. C. MEYER, J. HOFMANN, TS. PARK, **C. BUENO, P. MENENDEZ**, R. MARSCHALEK. (MLL RECOMBINOME CONSORTIUM). The MLL recombinome of acute leukemias in 2013. *LEUKEMIA* 2013; 27: 2165-76. **IF: 9,379 (JCR 2014)**. Times cited: 97. Q1
 23. **BUENO C, AYLLÓN V, MONTES R, ROMERO-MOYA D, NAVARRO-MONTERO O, RAMOS-MEJÍA V, REAL PJ, ARAÚZO-BRAVO M, MENENDEZ P**. FLT3 activation cooperates with MLL-AF4 fusion protein to abrogate the hematopoietic specification of hESCs. *BLOOD* 2013;121:3867-3878. **IF: 9,775 (JCR 2014)**. Times cited: 11. Q1
 24. **D. ROMERO-MOYA, C. BUENO, R. MONTES, O. NAVARRO-MONTERO, F.J. IBORRA, M. MARTÍN, P. MENÉNDEZ**. "Cord blood CD34+ hematopoietic cells with low levels of mitochondrial mass are enriched in hematopoietic repopulating stem cell function. *Haematologica* 2013; 98:1022-9 **IF: 5,868 (JCR 2014)**. Times cited: 14. Q1
 25. SUCH, ESPERANZA; GERMING, ULRICH; MALCOVATI, LUCA; CERVERA, JOSE; KUENDGEN, ANDREA; DELLA PORTA, MATTEO G.; NOMDEDEU, BENET; ARENILLAS, LEONOR; LUNO, ELISA;

- XICOY, BLANCA**; AMIGO, MARI L.; VALCARCEL, DAVID; NACHTKAMP, KATHRIN; AMBAGLIO, ILARIA; HILDEBRANDT, BARBARA; LORENZO, IGNACIO; CAZZOLA, MARIO; SANZ, GUILLERMO. Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. *BLOOD*. 2013; 121, 15 : 3005-3015. **IF: 9,775 (JCR 2014)**. Times Cited : 44. Q1
26. **JM RIBERA**. Optimal approach to the treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: How to best use all the available tools. *Leukemia & Lymphoma*. 2012 Jan. 13. **IF: 2.605 (JCR 2014)**. Times cited: 15. Q2
27. NAVARRO, ALFONS; MUNOZ, CARMEN; GAYA, ANNA; **DIAZ-BEYA, MARINA**; GEL, BERNAT; TEJERO, RUT; DIAZ, TANIA; MARTINEZ, ANTONIO; MONZO, MARIANO. MiR-SNPs as Markers of Toxicity and Clinical Outcome in Hodgkin Lymphoma Patients. *PLOS ONE*. 2013; 8, 5, e64716; 10.1371/journal.pone.0064716. **IF: 3,534 (JCR 2014)**. Times Cited: 9. Q1
28. **XICOY B**, MIRALLES P, **MORGADES M**, RUBIO R, VALENCIA ME, **RIBERA JM**. Long-term follow up of patients with human immunodeficiency virus infection and advanced stage Hodgkin's lymphoma treated with doxorubicin, bleomycin, vinblastine and dacarbazine. *Haematologica*. 2013 Aug;98(8):e85-6. doi:10.3324/haematol.2012.079921. Epub 2013 May 28. PubMed PMID: 23716563; PubMed Central PMCID: PMC3729888. **IF: 5,868 (JCR 2014)**. Times cited: 2 Q1
29. **V. ADEMA**, R. BEJAR. What lies beyond del(5q) in MDS? *Haematologica* 2013 (Dec); 98 (12): 1819-1821. **IF: 5,868 (JCR 2014)**. Times Cited: 1. Q1
30. MARTÍN-ANTONIO B, SUÁREZ-LLEDÓ M, ARROYES M, FERNÁNDEZ-AVILÉS F, MARTÍNEZ C, ROVIRA M, ESPIGADO I, GALLARDO D, BOSCH A, BUÑO I, MARTÍNEZ-LAPERCHE C, JIMÉNEZ-VELASCO A, DE LA CÁMARA R, BRUNET S, NIETO JB, **URBANO-ISPIZUA A**. A variant in IRF3 impacts on the clinical outcome of AML patients submitted to Allo-SCT. *Bone Marrow Transplant*. 2013; 48 (9): 1205-11. **I.F: 3.455 (JCR 2014)**. Times cited: 1
31. **JUNCA, JORDI**; **MILLA, FUENSANTA**; **XICOY, BLANCA**; GARCIA-CARO, MONTSE; RODRIGUEZ-HERNANDEZ, INES; AROSTEGUI, JUAN I. Pro-B acute lymphoblastic leukemia in a patient with severe congenital neutropenia: an unusual form of malignant evolution. *LEUKEMIA & LYMPHOMA*. 2013; 54, 10, 2325 – 2327. **IF: 2,605 (JCR 2014)**. Times Cited: 0. Q2
32. VILA BOU, JORDI; **JUNCA PIERA, JORDI**; TORRENT CATARINEU, ANNA; RODRIGUEZ FERNANDEZ, INES . Rhabdomyolysis and drepanocytic trait. *MEDICINA CLINICA (BCN)*. 2013. 141; 3; 136-137 10.1016/j.medcli.2012.10.022. **IF: 1,252**. Times Cited : 0. Q2

2014

1. **CASTAÑO J***, **MENENDEZ P***, BRUZOS C, SOUSA A, STRACCIA M, ZABALETA L, VAZQUEZ N, ZUBIARRAIN A, CANALS JM, CARVAJAL X, TORRECILLA M, SANCHEZ-PERNAUTE R, **GIORGETTI A**. Rapid and efficient neural conversion of human hematopoietic cells by *SOX2* and *c-MYC* Sendai vectors. *Stem Cell Rep* 2014. **IF: 5,365 (JCR 2014)**. Times Cited: 3. Q1

2. FREIJE A, CEBALLOS L, CAGIGAS M, MOLINUEVO R, ALONSO P, RODRIGUEZ R, **MENENDEZ P**, DE DIEGO E, GANDARILLAS A. Inactivation of p53 forces expel of human epidermal cells via replication stress, mitotic slippage and squamous differentiation. *Cell Rep* 2014 **IF: 8,358 (JCR 2014)**. Times Cited: 4. Q1
3. GUIU J, BERGEN DJ, ISLAM K, AYLLÓN V, NORTON L, RUIZ-HERGUIDO C, LÓPEZ-BIGAS N, **MENÉNDEZ P**, ESPINOSA L, BIGAS A. Identification of CDCA7 as a novel Notch transcriptional target involved in Hematopoietic Stem Cells emergence. *J Exp Med* 2014 . **IF: 12,515 (JCR 2014)**. Times Cited: 2. Q1
4. RAMOS-MEJÍA V, NAVARRO-MONTERO O, AYLLÓN V, **BUENO C**, ROMERO T, REAL PJ, **MENENDEZ P***. HOXA9 promotes hematopoietic commitment of human embryonic stem cells. *Blood* 2014. **IF: 10,452 (JCR 2014)**. Times Cited: 3. Q1
5. RODRÍGUEZ R, ROSU-MYLES M, ARAÚZO-BRAVO M, **HORRILLO A**, GÓNZALEZ-REY E, DELGADO M, **MENENDEZ P***. Human bone marrow stromal cells lose immunosuppressive and anti-inflammatory properties upon oncogenic transformation. *Stem Cells Reports* 2014; 3:606-619. *Cell Editorial*. **IF: 5, 365**. Times Cited: 2. Q1
6. VELASCO I, SALAZAR P, **ROMERO-MOYA D**, **CASTAÑO J**, **RAMOS-MEJIA V**, **GIORGETTI A**, **MENENDEZ P***. Generation of neurons from healthy individuals and neurological patients through induced pluripotency and direct conversion. *Stem Cells* 2014; 32:2811-2817. **IF: 6,523 (JCR 2014)**. Times Cited: 8. Q1
7. **BUENO C**, ROLDÁN M, ANGUITA E, **ROMERO-MOYA D**, ROSU-MYLES M, CAÑIZO C, GARCÍA R, GÓMEZ-CASARES M, FUSTER JL, JURADO M, DELGADO M, **MENENDEZ P***. Bone marrow mesenchymal stem cells from patients with aplastic anemia preserve functional and immune properties and do not contribute to the pathogenesis of the disease. *Haematologica* 2014; 99:1168-1175. **IF: 5,814 (JCR 2014)**. Times Cited: 4. Q1
8. RODRIGUEZ RM, SUAREZ-ALVAREZ B, SALVANÉS R, HUIDOBRO C, TORAÑO EG, GARCIA-PEREZ JL, LOPEZ-LARREA C, FERNANDEZ AF, **MENENDEZ P**, FRAGA MF. Role of BRD4 in hematopoietic differentiation of embryonic stem cells. *Epigenetics* 2014;9: 566-578. **IF: 4,708 (JCR 2014)** Times Cited: 4
9. RUBIO R, ABARRATEGI A, GARCÍA-CASTRO J, SUÁREZ C, TORNÍN J, SANTOS L, COLMENERO I, **MENENDEZ P***, RODRÍGUEZ R. Bone microenvironment signals are essential for osteosarcoma development from p53- and Rb-deficient mesenchymal stem cells. *Stem Cells* 2014; 32:1136-1148. **IF: 6,523 (JCR 2014)**. Times Cited: 5. Q1
10. PÉREZ-MATO M, RAMOS-CABRERO P, SOBRINO T, BLANCO M, RUBAN A, MIRELMAN D, **MENENDEZ P**, CASTILLO J, CAMPOS F. Human recombinant glutamate oxaloacetate transaminase 1 (GOT1) supplemented with oxaloacetate induces a protective effect after cerebral ischemia. *Cell Death & Dis* 2014; 5:992-1001. **IF: 5.014 (JCR 2014)**. Times Cited: 8. Q1
11. MONTES R, BURSEN A, MARSCHALEK R, PRELLE C, CHILLÓN C, **ROMERO-MOYÁ D**, **PRIETO C**, NAVARRO-MONTERO O, **BUENO C**, **MENENDEZ P***. Ligand-independent FLT3 activation does not cooperate with MLL-AF4 to immortalize/transform cord blood CD34+ cells. *LEUKEMIA* 2014; 28:666-674. **IF: 10,431 (JCR 2014)**. Times Cited: 3. Q1
12. **MORENO-MARTÍNEZ D**, **NOMDEDEU M**, **LARA-CASTILLO MC**, **ETXABE A**, **PRATCORONA M**, **TESI N**, **DÍAZ-BEYÁ M**, **ROZMAN M**, **MONTERRAT E**, **URBANO-ISPIZUA A**, **ESTEVE J**, **RISUEÑO**

- RM.** XIAP inhibitors induce differentiation and impair clonogenic capacity of acute myeloid leukemia stem cells. *Oncotarget* 2014; 5:4337-46. **IF: 6,359. (JCR 2014).** Times Cited: 0. Q1
13. CALVO X, NOMDEDEU M, NAVARRO A, TEJERO R, COSTA D, MUÑOZ C, PEREIRA A, PEÑA O, **RISUEÑO RM**, MONZÓ M, **ESTEVE J**, NOMDEDEU B. High levels of global DNA methylation are an independent adverse prognostic factor in a series of 90 patients with de novo myelodysplastic syndrome. *Leuk Res* 2014; 38:874-881. **IF: 2,351 (JCR 2014).** Times Cited: 3 Q3
 14. ROZMAN M, NAVARRO JT, ARENILLAS L, AVENTÍN A, GIMÉNEZ T, ALONSO E, PEREA G, CAMÓS M, NAVARRETE M, TUSET E, FLORENSA L, MILLÁ F, NOMDEDÉU J, DE LA BANDA E, DÍAZ-BEYÁ M, PRATCORONA M, GARRIDO A, NAVARRO B, BRUNET S, SIERRA J, **ESTEVE J**; Grup Català de Citologia Hematològica and Spanish CETLAM Group (Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas Mieloblásticas). Multilineage dysplasia is associated with a poorer prognosis in patients with de novo acute myeloid leukemia with intermediate-risk cytogenetics and wild-type NPM1. *Ann Hematol.* 2014; 93:1695-703. **IF: 2,634 (JCR 2014).** Times Cited: 2. Q2
 15. DÍAZ-BEYÁ M, BRUNET S, NOMDEDÉU J, TEJERO R, DÍAZ T, PRATCORONA M, TORMO M, RIBERA JM, ESCODA L, DUARTE R, GALLARDO D, HERAS I, QUEIPO DE LLANO MP, BARGAY J, MONZO M, SIERRA J, NAVARRO A, **ESTEVE J**; Cooperative AML group CETLAM (Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias). MicroRNA expression at diagnosis adds relevant prognostic information to molecular categorization in patients with intermediate-risk cytogenetic acute myeloid leukemia. *Leukemia.* 2014; 28:804-812. **IF: 10,431 (JCR 2014).** Times Cited: 12 Q1
 16. BÁEZ A, **MARTÍN-ANTONIO B**, PIRUAT JI, BARBADO MV, PRATS C, ALVAREZ-LADERAS I, CARMONA M, PÉREZ-SIMÓN JA, **URBANO-ISPIZUA A**. Gene and miRNA Expression Profiles of Hematopoietic Progenitor Cells Vary Depending on Their Origin. *Biol Blood Marrow Transplant.* 2014; 20:630-9. **IF: 3.404 (JCR 2014).** Times Cited: 1. Q2
 17. BÁEZ A, **MARTÍN-ANTONIO B**, PIRUAT JI, PRATS C, ALVAREZ-LADERAS I, BARBADO MV, CARMONA M, **URBANO-ISPIZUA A**, PÉREZ-SIMÓN JA. The Granulocyte colony-stimulating factor produces long-term changes on gene and miRNA expression profiles in CD34+ cells from healthy donors. *Haematologica* 2014; 99:243-51. **IF: 5,814 (JCR 2014).** Times Cited: 2 Q1
 18. SCHREZENMEIER H, MUUS P, SOCIÉ G, SZER J, **URBANO-ISPIZUA A**, MACIEJEWSKI JP, BRODSKY RA, BESSLER M, KANAKURA Y, ROSSE W, KHURSIGARA G, BEDROSIAN C, HILLMEN P. Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry. *Haematologica* 2014; 99(5):922-9. **IF: 5,814 (JCR 2014).** Times Cited: 7 Q1
 19. FARZAM P, LINDNER C, WEIGEL UM, SUAREZ M, **URBANO-ISPIZUA A**, DURDURAN T. Noninvasive characterization of the healthy human manubrium using diffuse optical spectroscopies. *Physiol Meas.* 2014; 35:1469-91. **IF: 1.888 (JCR 2014).** Times Cited: 5. Q2
 20. BASTIDA-LERTXUNDI N, LOPEZ-LOPEZ E; MARTIN-GUERRERO I, PIÑAN MA, PUIGGROS A, **SOLÉ F**, NAVAJAS A, GARCÍA-ORAD Á (2.014): Errors in the interpretation of copy number variations due to the use of public databases as reference. *Cancer Genetics.* 207(4):164-167. PMID: 24767712. **IF: 2,975 (JCR 2014).** Times Cited: 0 Q2
 21. CREE IA, DEANS Z, LIGTENBERG MJ, NORMANNO N, EDSJÖ A, ROULEAU E, **SOLÉ F**, THUNNISSEN E, TIMENS W, SCHUURING E, DEQUEKER E, MURRAY S, DIETEL M, GROENEN P,

- VAN KRIEKEN JH; for the European Society of Pathology Task Force on Quality Assurance in Molecular Pathology and the Royal College of Pathologists (2.014): Guidance for laboratories performing molecular pathology for cancer patients. *J Clin Pathol*. 2014 Jul 10. PMID: 25012948. **IF: 2,915 (JCR 2014)** Times Cited: 7 Q2
22. XOCHELLI A, BALIAKAS P, MOORE S, **SOLE F**, WICKHAM N, SALIDO M, ATHANASIADOU A, OSCIER D, STAMATOPOULOS K. Translocation t(2;7)(p11;q21-22): A rare genetic aberration translocation associated with B-CELL lymphoproliferative disorders of marginal zone origin (2.014): *Cancer Genetics*, 207 (3): 83-86. PMID: 25178943. **IF: 2,975 (JCR 2014)** Times Cited: 0. Q2
 23. DIAZ A, PUIG-BUTILLÉ JA, MUÑOZ C, COSTA D, DÍEZ A, GARCIA-HERRERA A, CARRERA C, BADENAS C, **SOLÉ F**, MALVEHY J, PUIG S, ALOS L (2.014): TERT gene amplification is associated with poor outcome in acral lentiginous melanoma. *Journal of the American Academy of Dermatology (letter to the editor)*. 71(4):839-841. PMID: 25219713 **IF: 4,449 (JCR 2014)**. Times Cited: 3. Q1
 24. SCHNEIDER RK, **ADEMÀ V**, HECKL D, JÄRÅS M, **MALLO M**, LORD AM, CHU A, MCCONKEY M, KRAMANN R, MULLALLY A, BEJAR R, **SOLÉ F**, EBERT BL (2.014): Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS. *Cancer Cell*. PMID: 25242043. **IF: 23,523 (JCR 2014)**. Times Cited: 18. Q1
 25. SERRANO MJ, ORTEGA FG, ALVAREZ-CUBERO MJ, NADAL R, SANCHEZ-ROVIRA P, SALIDO M, RODRÍGUEZ M, MACIÀ M, GARCÍA-PUCHE JL, DELGADO-RODRIGUEZ M, **SOLÉ F**, A. GARCÍA M, PERÁN M, ROSELL R, MARCHAL JA, LORENTE JA: EMT and EGFR in CTCs cytokeratin negative non-metastatic breast cancer. *Oncotarget* 2014; 5(17):7486-7497. PMID: 25277187. **IF: 6,359 (JCR 2014)**. Times Cited: 4. Q1
 26. **BATLLE M, MORGADES M, VIVES S, FERRÀ C, ORIOL A, SANCHO JM, MORENO M, MAGALLÓN L, RIBERA JM**. Usefulness and safety of oral cryotherapy in the prevention of oral mucositis after conditioning regimens with high-dose melphalan for autologous stem cell transplantation for lymphoma and myeloma. *European Journal of Haematology*. 2014 May 30]. **IF: 2.066 (JCR 2014)**. Times Cited: 3. Q3
 27. MUÑIZ C, MARTÍN-MARTÍN L, LÓPEZ A, SÁNCHEZ-GONZÁLEZ B, SALAR A, ALMEIDA J, **SANCHO JM, RIBERA JM**, et al. Contribution of cerebrospinal fluid sCD19 levels to the detection of CNS lymphoma and its impact on disease outcome. *Blood* 2014; 123:1864-9. **IF: 10,452 (JCR 2014)** Times Cited: 3. Q1
 28. **MOTLLÓ C, RIBERA JM, MORGADES M, GRANADA I**, MONTESINOS P, GONZÁLEZ-CAMPOS J, FERNÁNDEZ-ABELLÁN P, TORMO M, BETHENCOURT C, BRUNET S, HERNÁNDEZ-RIVAS JM, MORENOMJ, SARRÀ J, DEL POTRO E, BARBA P, BERNAL T, GRANDE C, **GRAU J, CERVERA J, FELIU E**; PETHEMA Group, Spanish Society of Hematology. Prognostic significance of complex karyotype and monosomal karyotype in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols. *Cancer* 2014 Aug 12. doi: 10.1002/cncr.28950. PubMed PMID: 25116331. **IF: 5,068 (JCR 2014)**. Times Cited: 2. Q1
 29. **RIBERA JM, ORIOL A, MORGADES M**, MONTESINOS P, SARRÀ J, GONZÁLEZ-CAMPOS J, BRUNET S, TORMO M, FERNÁNDEZ-ABELLÁN P, GUÀRDIA R, BERNAL MT, ESTEVE J, BARBA P, MORENO MJ, BERMÚDEZ A, CLADERA A, ESCODA L, GARCÍA-BOYERO R, DEL POTRO E, BERGUAJ, AMIGO ML, GRANDE C, RABUÑAL MJ, HERNÁNDEZ-RIVAS JM, **FELIU E**. Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults

- according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial. *J Clin Oncol*. 2014; 32(15):1595-604. **IF: 17.960 (JCR 2014)**. Times Cited: 20. Q1
30. **XICOY B, RIBERA JM, MÜLLER M, GARCÍA O, HOFFMANN C, ORIOL A, HENTRICH M, GRANDE C, WASMUTH JC, ESTEVE J, VAN LUNZEN J, DEL POTRO E, KNECHTEN H, BRUNET S, MAYR C, ESCODA L, SCHOMMERS P, ALONSO N, VALL-LLOVERA F, PÉREZ M, MORGADES M, GONZÁLEZ J, FERNÁNDEZ A, THODEN J, GÖKBUGET N, HOELZER D, FÄTKENHEUER G, WYEN C; PETHEMA Group and German HIV Lymphoma Cohort.** Dose-intensive chemotherapy including rituximab is highly effective but toxic in human immunodeficiency virus-infected patients with Burkitt lymphoma/leukemia: parallel study of 81patients. *Leuk Lymphoma*. 2014; 55(10):2341-8. **IF: 2,891 (JCR 2014)**. Times Cited: 4. Q2
 31. PIÑANA JL, SANZ J, PICARDI A, **FERRÁ C**, MARTINO R, BARBA P, GONZALEZ-VICENT M, PASCUAL MJ, MARTÍN C, VERDEGUER A, DE HEREDIA CD, MONTESINOS P, RIBERA JM, SANZM, ARCESE W, SANZ G; GETH groups; GITMO groups. Umbilical cord blood transplantation from unrelated donors in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. *Haematologica*.2014; 99 (2):378-84. **IF: 5.868 (JCR 2014)**. Times Cited: 4. Q1
 32. RUGGERI A, SANZ G, BITTENCOURT H, SANZ J, RAMBALDI A, VOLT F, YAKOUB-AGHA I,**RIBERA JM**, MANNONE L, SIERRA J, MOHTY M, SOLANO C, NABHAN S, ARCESE W, GLUCKMANE, LABOPIN M, ROCHA V; Eurocord and Acute Leukemia Working Party of European Blood and Marrow Transplant Group. Comparison of outcomes after single or double cord blood transplantation in adults with acute leukemia using different types of myeloablative conditioning regimen, a retrospective study on behalf of Eurocordand the Acute Leukemia Working Party of EBMT. *Leukemia*. 2014; 28(4):779-86. **IF: 9.379 (JCR 2014)**. Times Cited: 23. Q1
 33. TUCUNDUVA L, RUGGERI A, SANZ G, FURST S, SOCIÉ G, MICHALLET M, ARCESEW,MILPIED N, YAKOUB-AGHA I, LINKESCH W, CORNELISSEN J, MANNONE L, IORI AP, **RIBERA JM**, SANZ J, MONTESINOS P, PURTILL D, LABOPIN M, GLUCKMAN E, MOHTY M, ROCHA V.Risk factors for outcomes after unrelated cord blood transplantation for adults with acute lymphoblastic leukemia: a report on behalf of Eurocord and the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. *Bone Marrow Transplant*. 2014; 49(7):887-94. **IF: 3,570 (JCR 2014)**. Times Cited: 3. Q2
 34. **JIMÉNEZ MJ, FERRA C, GARCÍA O, DE ARRIBA F, JIMÉNEZ S, INSUNZA A, CALABUIG M, MANTECON A, SÁNCHEZ J, TORRES M, BALSALOBRE P, LINIO J, JIMÉNEZ A, FELIU E, RIBERA JM.** The commitment and evaluation of the quality management plan by professionals from accredited stem cell transplant centers in Spain. *Bone Marrow Transplant*. 2014 JUL; 49 (7):990-2. **IF: 3,570 (JCR 2014)**. Times Cited: 0. Q2
 35. BARTA SK, XUE X, WANG D, LEE JY, KAPLAN LD, **RIBERA JM, ORIOL A**, SPINA M, TIRELLI U, BOUE F, WILSON WH, WYEN C, DUNLEAVY K, NOY A, SPARANO JA. A new prognostic score for AIDS-related lymphomas in the Rituximab-era. *Haematologica*. 2014 Aug 22. pii: haematol.2014.111112. **IF: 5.868 (JCR 2014)**. Times Cited: 0. Q1
 36. **RIBERA J, ZAMORA L, JUNCÀ J, RODRIGUEZ I, MARCÉ S, CABEZÓN M, MILLÁ F.** Usefulness of IGH/TCR PCR studies in lymphoproliferative disorders with inconclusive clonality by flow cytometry. *Cytometry Part B- Clin Cytom* 2014;86: 25-31. **IF: 2,398 (JCR 2014)**. Times Cited: 0. Q1

37. BENBOUBKER L, DIMOPOULOS MA, DISPENZIERI A, CATALANO J, BELCH AR, CAVO M, PINTO A, WEISEL K, LUDWIG H, BAHNIS N, BANOS A, TIAB M, DELFORGE M, CAVENAGH J, GERALDES C, LEE JJ, CHEN C, **ORIOLO A**, DE LA RUBIA J, QIU L, WHITE DJ, BINDER D, ANDERSON K, FERMAND JP, MOREAU P, ATTAL M, KNIGHT R, CHEN G, VAN OOSTENDORP J, JACQUES C, ERVIN-HAYNES A, AVET-LOISEAU H, HULIN C, FACON T. FIRST Trial Team. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. *N Engl J Med*. 2014 Sep 4; 371(10):906-17. doi: 10.1056/NEJMoa1402551. **IF: 55,873 (JCR 2014)**. Times Cited: 62. Q1
38. DE FALCO L, SILVESTRI L, KANNENGIESSER C, MORÁN E, OUDIN C, RAUSA M, BRUNO M, ARANDA J, ARGILES B, YENICESU I, FALCON-RODRIGUEZ M, YILMAZ-KESKIN E, KOCAK U, BEAUMONT C, CAMASCHELLA C, IOLASCON A, GRANDCHAMP B, **SANCHEZ M**. Functional and clinical impact of novel Tmprss6 mutations in Iron-Refractory Iron-Deficiency Anaemia patients and genotype-phenotype studies. *Hum Mutat*. 2014 Aug 25. doi: 10.1002/humu.22632. **IF: 5,340 (JCR 2014)**. Times Cited: 3. Q1
39. TEIXEIRA E, BORLIDO-SANTOS J, BRISSOT P, BUTZECK B, COURTOIS F, EVANS RW, FERNAU J, NUNES JA, MULLETT M, PANEQUE M, PINEAU B, PORTO G, SORRILL R, **SANCHEZ M**, SWINKELS DW, TOSKA K, VARKONYI J. the EFAPH, the European Federation of Associations of Patients with Haemochromatosis. The importance of the general practitioner as an information source for patients with hereditary haemochromatosis. *Patient Educ Couns*. 2014 May 5. PPI: S0738-3991(14)00178-5. doi: 10.1016/j.pec.2014.04.017. **IF: 2,199 (JCR 2014)**. Times Cited: 3. Q1
40. OST A, LEMPRADL A, CASAS E, WEIGERT M, TIKO T, DENIZ M, PANTANO L, BOENISCH U, ITS KOV PM, STOECKIUS M, RUF M, RAJEWSKY N, REUTER G, IOVINO N, RIBEIRO C, ALENIUS M, HEYNE S, **VAVOURI T**, POSPISILIK JA. Paternal diet defines offspring chromatin state and intergenerational obesity. *Cell*. **FI: 32,242 (JCR 2014)**. Times Cited: 22. Q1
41. MARTINEZ-TRILLOS, ALEJANDRA; PINYOL, MAGDA; NAVARRO, ALBA; AYMERICH, MARTA; JARES, PEDRO; JUAN, MANEL; ROZMAN, MARIA; COLOMER, DOLORS; DELGADO, JULIO; GINE, EVA; GONZALEZ-DIAZ, MARCOS; HERNANDEZ-RIVAS, JESUS M.; COLADO, ENRIQUE; RAYON, CONSOLACION; PAYER, ANGEL R.; JOSE TEROL, MARIA; NAVARRO, BLANCA; QUESADA, VICTOR; PUENTE, XOSE S.; **ROZMAN, CIRIL**; LOPEZ-OTIN, CARLOS; CAMPO, ELIAS; LOPEZ-GUILLERMO, ARMANDO; VILLAMOR, NEUS. Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome. *BLOOD*. 2014. 123; 24; 3790 – 3796. 10.1182/blood-2013-12-543306 **FI: 10,452 (JCR 2014)**. Times Cited: 11. Q1
42. GARCIA CADENAS, IRENE; VALCARCEL, DAVID; MARTINO, RODRIGO; PINANA, J L; BARBA, PERE; NOVELLI, SILVANA; ESQUIROL, ALBERT; GARRIDO, ANA; SAAVEDRA, SILVANA; GRANELL, MIQUEL; MORENO, CAROL; BRIONES, JAVIER; **BRUNET, SALUT**; **SIERRA, JORGE**. Impact of cyclosporine levels on the development of acute graft versus host disease after reduced intensity conditioning allogeneic stem cell transplantation. *Mediators of Inflammation*. 2014; 620682; 10.1155/2014/620682. **FI: 3,236 (JCR 2014)**. Times Cited: 1. Q2
43. DIAZ, ALBA; ANTON PUIG-BUTILLE, JOAN; VALERA, ALEXANDRA; MUNOZ, CONCHA; COSTA, DOLORS; GARCIA-HERRERA, ADRIANA; CARRERA, CRISTINA; **SOLE, FRANCESC**; MALVEHY, JOSEP; PUIG, SUSANA; ALOS, LLUCIA. TERT and AURKA Gene Copy Number Gains Enhance the Detection of Acral Lentiginous Melanomas by Fluorescence in Situ Hybridization. *JOURNAL OF MOLECULAR DIAGNOSTICS*. 2014. 16; 2; 198 – 206. 10.1016/j.jmoldx.2013.10.009. **FI: 4,851 (JCR 2014)**. Times Cited: 1. Q1

44. JUNCA, JORDI; GARCIA-CARO, MONTSE; GRANADA, ISABEL; RODRIGUEZ-HERNANDEZ, INES; TORRENT, ANNA; MORGADES, MIREIA; RIBERA, JOSEP-MARIA; MILLA, FUENSANTA; FELIU, EVARIST. Correlation of CD11b and CD56 expression in adult acute myeloid leukemia with cytogenetic risk groups and prognosis. *ANNALS OF HEMATOLOGY*. 2014. 93; 9, 1483 – 1489. 10.1007/s00277-014-2082-4. **FI: 2,634 (JCR 2014)**. Times Cited: 5. Q2
45. DELGADO, JULIO; PEREIRA, ARTURO; VILLAMOR, NEUS; LOPEZ-GUILLERMO, ARMANDO; **ROZMAN, CIRIL**. Survival analysis in hematologic malignancies: recommendations for clinicians. *HAEMATOLOGICA*. 2014. 99; 9, 1410 – 1420. 10.3324/haematol.2013.100784. **FI: 5,814 (JCR 2014)**. Times Cited: 4. Q1
46. XICOY B, JIMÉNEZ MJ, GARCÍA O, BARGAY J, MARTÍNEZ-ROBLES V, BRUNET S, ARILLA MJ, PÉREZ DE OTEYZA J, ANDREU R, CASAÑO FJ, CERVERO CJ, BAILÉN A, DÍEZ M, GONZÁLEZ B, VICENTE AI, PEDRO C, BERNAL T, LUÑO E, CEDENA MT, PALOMERA L, SIMIELE A, CALVO JM, MARCO V, GÓMEZ E, GÓMEZ M, GALLARDO D, MUÑOZ J, DE PAZ R, **GRAU J, RIBERA JM**, BENLLOCH LE, SANZ G. Results of treatment with azacitidine in patients aged ≥ 75 years included in the Spanish Registry of Myelodysplastic Syndromes. *Leuk & Lymphoma*. 2013 Sep 16. PubMed PMID: 23952246. **IF: 2,891 (JCR 2014)**. Times Cited: 4. Q2
47. TUCUNDUVA L, RUGGERI A, SANZ G, FURST S, SOCIÉ G, MICHALLET M, ARCESEW, MILPIED N, YAKOUB-AGHA I, LINKESCH W, CORNELISSEN J, MANNONE L, IORI AP, **RIBERA JM**, SANZ J, MONTESINOS P, PURTILL D, LABOPIN M, GLUCKMAN E, MOHTY M, ROCHA V. Risk factors for outcomes after unrelated cord blood transplantation for adults with acute lymphoblastic leukemia: a report on behalf of Eurocord and the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. *Bone Marrow Transplant*. 2014; 49(7):887-94. **IF: 3,570 (JCR 2014)**. Times Cited: 3. Q2
48. SANCHEZ-GARCIA, JOAQUIN; DEL CANIZO, CONSUELO; LORENZO, IGNACIO; NOMDEDEU, BENET; LUNO, ELISA; DE PAZ, RAQUEL; **XICOY, BLANCA**; VALCARCEL, DAVID; BRUNET, SALUT; MARCO-BETES, VICTOR; GARCIA-PINTOS, MARTA; OSORIO, SANTIAGO; TORMO, MAR; BAILEN, ALICIA; CERVERO, CARLOS; RAMOS, FERNANDO; DIEZ-CAMPELO, MARIA; SUCH, ESPERANZA; ARRIZABALAGA, BEATRIZ; AZACETA, GEMMA; BARGAY, JOAN; ARILLA, MARIA J.; FALANTES, JOSE; SERRANO-LOPEZ, JOSEFINA; SANZ, GUILLERMO F. Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion. *BRITISH JOURNAL OF HAEMATOLOGY*. 166; 2, 189-201. 10.1111/bjh.12876. **IF: 4,971 (JCR 2014)**. Times Cited: 2. Q1
49. **MOTLLÓ C, SANCHO JM, GRIFOLS JR, JUNCÀ J, MORGADES M, ESTER A, RODRÍGUEZ I, VIVES S, BATLLE M, GUARDIA R, FERRÀ C, GALLARDO D, MILLÀ F, FELIU E, RIBERA JM**. Mobilization and engraftment of peripheral blood stem cells in healthy related donors > 55 years old. *Cytotherapy*. 2014; 16:406-11. **IF: 3,293 (JCR 2014)**. Times Cited: 2. Q2
50. **ORIOI, ALBERT; MOTLLO, CRISTINA**. New drugs in the treatment of multiple myeloma. *Med Clin (BCN)*. 2014. 143; 6, 268-274. 10.1016/j.medcli.2013.10.012. **IF: 1,417 (JCR 2014)**. Times Cited: 0. Q2
51. FERNÁNDEZ-SOJO J, VIVES S, OLIVERAS VILÀ T, **RIBERA JM**. Exudative pericardial effusion and oligoarthritis in a patient newly diagnosed with myelodysplastic syndrome. *Med Clin (Barc)*. 2013 Oct 29. doi: 10.1016/j.medcli.2013.09.009. **IF: 1,417 (JCR 2014)**. Times Cited: 0. Q2
52. MARTÍNEZ N, ALMARAZ C, VAQUÉ JP, VARELA I, DERDAK S, BELTRAN S, MOLLEJO M, CAMPOS-MARTIN Y, AGUEDA L, RINALDI A, KWEE5 I, GUT M, BLANC J, OSCIER D,

MARTINEZ-LOPEZ J, SALAR A, **SOLE F**, RODRIGUEZ-PERALTO JL, DÍEZ C, GARCÍA JF, FRAGA M, SEBASTIÁN E, ALVÉS J, MENÁRGUEZ J, GONZÁLEZ-CARRERÓ J, FELIPE CASADO J, BAYES M, BERTONI F, GUT I, PIRIS MA (2.014):. Whole exome sequencing in splenic marginal 1 zone lymphoma reveals mutations in genes involved in marginal zone differentiation. *Leukemia*. 28(6):1334-40. PMID: 24296945. **IF: 10,431 (JCR 2014)**. Times Cited: 17. Q1

53. PUIGGROS, ANNA; VENTURAS, MARTA; SALIDO, MARTA; BLANCO, GONZALO; FERNANDEZ-RODRIGUEZ, CONCEPCION; COLLADO, ROSA; VALIENTE, ALBERTO; **RUIZ-XIVILLE, NEUS**; CARRIO, ANA; JOSE ORTUNO, FRANCISCO; LUNO, ELISA; JOSE CALASANZ, MARIA; TERESA ARDANAZ, MARIA; PINAN, MARIA ANGELES; TALAVERA, ELISABET; TERESA GONZALEZ, MARIA; ORTEGA, MARGARITA; MARUGAN, ISABEL; FERRER, ANA; GIMENO, EVA; BELLOSILLO, BEATRIZ; DELGADO, JULIO; ANGEL HERNANDEZ, JOSE; MARIA HERNANDEZ-RIVAS, JESUS; ESPINET, BLANCA. Interstitial 13q14 Deletions Detected in the Karyotype and Translocations with Concomitant Deletion at 13q14 in Chronic Lymphocytic Leukemia: Different Genetic Mechanisms but Equivalent Poorer Clinical Outcome. *GENES CHROMOSOMES & CANCER*. 53; 9, 788-797. 10.1002/gcc.22188. **IF: 4,041 (JCR 2014)**. Times Cited: 4. Q1
54. **JUNCÀ J, BOTÍN T, VILA J, NAVARRO JT, MILLÁ F**. Adult T-cell leukemia/lymphoma with an unusual CD1a positive phenotype. *Cytometry Part B -Clinical Cytometry*. 2014; 86: 292-296. **IF: 2,398 (JCR 2014)**. Times Cited: 0. Q2
55. **JUNCA, JORDI; BOTIN, TERESA; RODRIGUEZ-HERNANDEZ, INES; MILLA, FUENSANTA**. CD11b Expression in Acute Promyelocytic Leukemia. *AMERICAN JOURNAL OF CLINICAL PATHOLOGY*. 2014: 141; 6; 900-900. 10.1309/AJCPAORG0M1DPRWD. **IF: 2,514 (JCR 2014)**. Times Cited: 0. Q2

2015

1. SORIA-VALLES C, OSORIO FG, GUTIÉRREZ-FERNÁNDEZ A, DE LOS ANGELES A, **BUENO C, P. MENÉNDEZ**, DALEY GQ, FREIJE JMP & LÓPEZ-OTÍN C. NF-κB activation impairs somatic cell reprogramming in ageing. *Nature Cell Biol* 2015 **IF: 19,679 (JCR 2014)**. Times Cited: 3 Q1.
2. AYLON V, **BUENO C**, RAMOS-MEJÍA V, REAL P, ROMERO T, NAVARRO-MONTERO O, GARCÍA-LEÓN MJ, TORIBIO ML, BIGAS A, **MENENDEZ P***. The Notch ligand DLL4 marks human hematoendothelial progenitors and regulates their hematopoietic vs endothelium fate. *Leukemia* 2015. **IF. 10,431. (JCR 2014)**. Times Cited: 2 Q1
3. PINO-BARRIO MJ, GARCÍA-GARCÍA E, **MENÉNDEZ P**, MARTÍNEZ-SERRANO A. V-Myc immortalization of human neural stem cells induces self-renewal without activating a complete reprogrammed-like status. *PLoS ONE* 2015; 10: e0118499. **IF: 3,234. (JCR 2014)**. Times Cited: 1 Q1
4. ALFRANCA A, MARTÍNEZ-CRUZADO L, TORNÍN J, ABARRATEGI A, AMARAL T, DE ALAVA E, **MENÉNDEZ P**, GARCÍA-CASTRO J, RODRÍGUEZ R. Bone microenvironment signals in osteosarcoma development. *Cell Mol Life SCI*. 2015 (in press). **IF: 5.888. (JCR 2014)**. Times Cited: 1 Q1
5. QI S, FANG Z, WANG D, **MENENDEZ P**, YAO K, JI J. Induced Pluripotency by Defined Factors: Prey of Oxidative Stress. *Stem Cells* 2015; 33:1371-1376. **IF: 6,523. (JCR 2014)**. Times Cited: 1 Q1

6. TOSCANO M, NAVARRO-MONTERO O, AYLON V, RAMOS-MEJIA V, **BUENO C**, ROMERO T, COBO M, MARTIN F, **MENENDEZ P***, P. REAL*. SCL/TAL1-mediated transcriptional network enhances megakaryocytic differentiation of human embryonic stem cells. *Mol Ther* 2015; 23:158-170. **IF: 6.227. (JCR 2014)**. Times Cited: 1. Q1
7. MARTÍN-ANTONIO B, NAJJAR A, ROBINSON S, CHEW C, LI S, YVON E, THOMAS M, MCNIECE I, ORLOWSKI R, MUNOZ-PINEDO C, **BUENO C**, **MENENDEZ P**, FERNÁNDEZ DE LARREA C, **URBANO-ISPIZUA A**, SHPALL E, SHAH N. Transmissible Cytotoxicity Of Multiple Myeloma Cells By Cord Blood-Derived NK Cells Is Mediated By Vesicle Trafficking. *Cell Death Diff* 2015; 22:96-107. **IF: 8.184. (JCR 2014)**. Times Cited: 2. Q1
8. FERNÁNDEZ AF, BAYÓN GF, URDINGUIO RG, TORAÑO EG, GARCÍA M, CARELLA A, PETRUS-REURER S, FERRERO C, MARTINEZ-CAMBLOR P, CUBILLO I, GARCÍA-CASTRO J, DELGADO-CALLE J, RIANCHO JA, **BUENO C**, **MENÉNDEZ P**, MENTINK A, MARESCHI K, CLAIRE F, FAGNANI C, MEDDA E, TOCCACELI V, BRESCIANINI S, MORAN S, ESTELLER M, STOLZING A, DE BOER J, NISTICÒ L, STAZI MA, FRAGA MF. H3K4me1 marks DNA regions hypomethylated during aging in stem and differentiated cells. *Genome Res* 2015; 25:27-40. **IF. 14.630. (JCR 2014)**. Times Cited: 5. Q1
9. NADAL R, SALIDO M, NONELL L, RODRÍGUEZ-RIVERA M, PUIGDECANET E, MACIÀ M, COROMINAS JM, SERRANO MJ, LORENTE JA, **SOLÉ F**. Combined analysis of copy number alterations by single-nucleotide polymorphism array and MYC status in non-metastatic breast cancer patients: comparison according to the circulating tumor cell status. *Tumor Biology* 2015; 36(2):711-718. PMID: 2528675. **IF 3,611. (JCR 2014)**. Times Cited: 1. Q2
10. MOHTY M, MALARD F, ABECASSIS M, AERTS E, ALASKAR AS, ALJURF M, ARAT M, BADER P, BARON F, BAZARBACHI A, BLAISE D, CICERI F, CORBACIOGLU S, DALLE JH, DUARTE RF, FUKUDA T, HUYNH A, MASSZI T, MICHALLET M, NAGLER A, NICHONGHAILE M, PAGLUICA T, PETERS C, PETERSEN FB, RICHARDSON PG, RUUTU T, SAVANI BN, WALLHULT E, YAKOUB-AGHA I, **CARRERAS E**. Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT). *Bone Marrow Transplant* 2015 Jun;50(6):781-9. doi: 10.1038/bmt.2015.52.. **IF. 3,570. (JCR 2014)**. Times Cited: 4. Q2
11. **CARRERAS E**. How I manage sinusoidal obstruction syndrome after haematopoietic cell transplantation. *Br J Haematol* 2015 Feb;168(4):481-91. doi: 10.1111/bjh.13215. Epub 2014 Nov 17. **IF: 4,971. (JCR 2014)**. Times Cited: 4. **Q1**
12. QUEIRÓS A, VILLAMOR N, CLOT G, MARTINEZ-TRILLOS A, KULIS M, NAVARRO A, MURGA PENAS EM, JAYNE S, MAJID A, RICHTER J, BERGMANN A, KOLAROVA J, ROYO C, RUSSIÑOL N, CASTELLANO G, PINYOL M, BEA S, SALAVERRIA I, LÓPEZ-GUERRA M, COLOMER D, AYMERICH M, ROZMAN M, DELGADO J, GINÉ E, GONZÁLEZ M, PUENTE XS, SIEBERT R, DYER M, LÓPEZ-OTÍN C, **ROZMAN C**, CAMPO E, LOPEZ-GUILLERMO A, MARTÍN-SUBERO JI. A B-cell epigenetic signature defines three biological subgroups of chronic lymphocytic leukemia with clinical impact. *Leukemia* 2015 Mar; 29(3):598-605. doi: 10.1038/leu.2014.252.. **IF.10,431. (JCR 2014)**. Times Cited: 3. Q1.
13. FALANTES JF, TRUJILLO P, PIRUAT JI, CALDERÓN C, MÁRQUEZ-MALAVAR FJ, MARTÍN-ANTONIO B, MILLÁN A, GÓMEZ M, GONZÁLEZ J, MARTINO ML, MONTERO I, PARODY R, ESPIGADO I, **URBANO-ISPIZUA A**, PÉREZ-SIMÓN JA. Overexpression of GYS1, MIF, and MYC is associated with adverse outcome and poor response to azacitidine in myelodysplastic syndromes and

- acute myeloid leukemia. Clin Lymphoma Myeloma Leuk 2015 Apr; 15(4):236-44. doi: 10.1016/j.clml.2014.10.003. Epub 2014 Oct 23. **IF.2,020. (JCR 2014)**. Times Cited: 4. Q3
14. ARORA M, HEMMER MT, AHN KW, KLEIN JP, CUTLER CS, **URBANO-ISPIZUA A**, COURIEL DR, ALOUSI AM, GALE RP, INAMOTO Y, WEISDORF DJ, LI P, ANTIN JH, BOLWELL BJ, BOYIADZIS M, CAHN JY, CAIRO MS, ISOLA LM, JACOBSON DA, JAGASIA M, KLUMPP TR, PETERSDORF EW, SANTARONE S, SCHOUTEN HC, WINGARD JR, SPELLMAN SR, PAVLETIC SZ, LEE SJ, HOROWITZ MM, FLOWERS ME. Center for International Blood and Marrow Transplant Research chronic graft-versus-host disease risk score predicts mortality in an independent validation cohort. Biol Blood Marrow Transplant 2015 Apr; 21(4):640-5. doi: 10.1016/j.bbmt.2014.10.022. **IF. 3,404. (JCR 2014)**. Times Cited: 0. Q2
 15. ROSIÑOL L, JIMÉNEZ R, ROVIRA M, MARTÍNEZ C, FERNÁNDEZ-AVILÉS F, MARÍN P, SUÁREZ-LLEDÓ M, GUTIÉRREZ-GARCÍA G, FERNÁNDEZ DE LARREA C, CARRERAS E, **URBANO-ISPIZUA A**, BLADÉ J. Allogeneic hematopoietic SCT in multiple myeloma: long-term results from a single institution. Bone Marrow Transplant 2015 May; 50(5):658-62. doi: 10.1038/bmt.2014.320. **IF. 3,578. (JCR 2014)**. Times Cited: 2. Q2
 16. INAMOTO Y, FLOWERS ME, WANG T, **URBANO-ISPIZUA A**, HEMMER MT, CUTLER CS, COURIEL DR, ALOUSI AM, ANTIN JH, GALE RP, GUPTA V, HAMILTON BK, KHARFAN-DABAJA MA, MARKS DI, RINGDÉN OT, SOCIÉ G, SOLH MM, AKPEK G, CAIRO MS, CHAO NJ, HAYASHI RJ, NISHIHORI T, RESHEF R, SAAD A, SHAH A, TESHIMA T, TALLMAN MS, WIRK B, SPELLMAN SR, ARORA M, MARTIN PJ. Tacrolimus versus cyclosporine after hematopoietic cell transplantation for acquired aplastic anemia. Biol Blood Marrow Transplant 2015 May 29. pii: S1083-8791(15)00380-8. doi: 10.1016/j.bbmt.2015.05.023. **I.F. 3,404. (JCR 2014)**. Times Cited: 0. Q2
 17. **URBANO-ISPIZUA A**, PAVLETIC SZ, FLOWERS ME, KLEIN JP, ZHANG MJ, CARRERAS J, MONTOTO S, PERALES MA, ALJURF MD, AKPEK G, BREDESON CN, COSTA LJ, DANDROY C, FREYTES CO, FUNG HC, GALE RP, GIBSON J, HAMADANI M, HAYASHI RJ, INAMOTO Y, INWARDS DJ, LAZARUS HM, MALONEY DG, MARTINO R, MUNKER R, NISHIHORI T, OLSSON RF, RIZZIERI DA, RESHEF R, SAAD A, SAVANI BN, SCHOUTEN HC, SMITH SM, SOCIÉ G, WIRK B, YU LC, SABER W. The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen. Biol Blood Marrow Transplant 2015 May 15. pii: S1083-8791(15)00333-X. doi: 10.1016/j.bbmt.2015.05.010 **I.F. 3,404.(JCR 2014)**. Times Cited: 0. Q2
 18. CALVO X, NOMDEDEU M, SANTACRUZ R, MARTÍNEZ N, COSTA D, PEREIRA A, ESTRADA N, XICOY B, **ESTEVE J**, NOMDEDEU B. Comparison of three prognostic scoring systems in a series of 146 cases of chronic myelomonocytic leukemia (CMML): MD Anderson prognostic score (MDAPS), CMML-specific prognostic scoring system (CPSS) and Mayo prognostic model. A detailed review of prognostic factors in CMML. Leuk Res. 2015 Jul 23. pii: S0145-2126(15)30324-6. doi: 10.1016/j.leukres.2015.05.017. PubMed PMID: 26354683. **IF. 2.351. (JCR 2014)**. Times Cited: 0. Q3
 19. NORIEGA V, MARTÍNEZ-LAPERCHE C, BUCES E, PION M, SÁNCHEZ-HERNÁNDEZ N, MARTÍN-ANTONIO B, GUILLEM V, BOSCH-VIZCAYA A, BENTO L, GONZÁLEZ-RIVERA M, BALSALOBRE P, KWON M, SERRANO D, GAYOSO J, DE LA CÁMARA R, BRUNET S, ROJAS-CONTRERAS R, NIETO JB, MARTÍNEZ C, GÓNZALEZ M, ESPIGADO I, VALLEJO JC, SAMPOL A, JIMÉNEZ-VELASCO A, **URBANO-ISPIZUA A**, SOLANO C, GALLARDO D, DÍEZ-MARTÍN JL, BUÑO I; SPANISH HEMATOPOIETIC STEM CELL TRANSPLANTATION AND CELL THERAPY GROUP (GETH). The

Genotype of the Donor for the (GT)_n Polymorphism in the Promoter/Enhancer of FOXP3 Is Associated with the Development of Severe Acute GVHD but Does Not Affect the GVL Effect after Myeloablative HLA-Identical Allogeneic Stem Cell Transplantation. *PLoS One*. 2015 Oct 16;10(10):e0140454. doi: 10.1371/journal.pone.0140454. eCollection 2015. PMID: 26473355. **IF: 3,234. (JCR 2014)**. Times Cited: 0. Q1

20. DÍAZ-BEYÁ M, BRUNET S, NOMDEDÉU J, CORDEIRO A, TORMO M, ESCODA L, RIBERA JM, ARNAN M, HERAS I, GALLARDO D, BARGAY J, QUEIPO DE LLANO MP, SALAMERO O, MARTÍ JM, SAMPOL A, PEDRO C, HOYOS M, PRATCORONA M, CASTELLANO JJ, NOMDEDEU M, RISUEÑO RM, SIERRA J, MONZÓ M, NAVARRO A, **ESTEVE J**. The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute. *Blood Cancer J*. 2015 Oct 2; 5:e352. doi: 10.1038/bcj.2015.76. PubMed PMID: 26430723. **IF: 3.467. (JCR 2014)**. Times Cited: 0. Q2
21. DÍAZ-BEYÁ M, BRUNET S, NOMDEDÉU J, PRATCORONA M, CORDEIRO A, GALLARDO D, ESCODA L, TORMO M, HERAS I, RIBERA JM, DUARTE R, DE LLANO MP, BARGAY J, SAMPOL A, NOMDEDEU M, RISUEÑO RM, HOYOS M, SIERRA J, MONZO M, NAVARRO A, **ESTEVE J**; COOPERATIVE AML GROUP CETLAM. The lincRNA HOTAIRM1, located in the HOXA genomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature. *Oncotarget*. 2015 Oct 13; 6(31):31613-27. doi: 10.18632/oncotarget.5148. PubMed PMID: 26436590. **IF: 6.359. (JCR 2014)**. Times Cited: 0. Q1
22. NOMDEDEU M, LARA-CASTILLO MC, ETXABE A, CORNET-MASANA JM, PRATCORONA M, DÍAZ-BEYÁ M, CALVO X, ROZMAN M, COSTA D, **ESTEVE J**, **RISUEÑO RM**. Treatment with G-CSF reduces acute myeloid leukemia blast viability in the presence of bone marrow stroma. *Cancer Cell Int*. 2015 Dec 21;15:122. doi: 10.1186/s12935-015-0272-3. eCollection 2015. PMID: 26696777. **IF: 2,766. (JCR 2014)**. Times Cited: 4. Q3
23. **SANJUAN-PLA A**, **BUENO C**, **PRIETO C**, ACHA P, STAM RW, MARSCHALEK R, **MENENDEZ P**. Revisiting the biology of infant t(4;11)/MLL-AF4+ B-cell acute lymphoblastic leukemia. *BLOOD* 2015; 126:2676-85. **IF: 10.452. (JCR 2014)**. Times Cited: 0. Q1
24. BRAULKE F, MÜLLER-THOMAS C, GÖTZE K, PLATZBECKER U, GERMING U, BRÜMMENDORF TH, NOLTE F, GIAGOUNIDIS A, LÜBBERT M, GREENBERG PL, **SOLÉ F**, **MALLO M**, BENNETT JM, SLOVAK ML, OHYASHIKI M, LE BEAU MM, TÜCHLER H, SHIRNESHAN K, PFEILSTÖCKER M, NÖSSLINGER T, HILDEBRANDT B, AUL C, STAUDER R, VALENT P, FONATSCH CH, TRÜMPER L, HAASE D, SCHANZ J. Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control group. *Haematologica* 2015; 100(2):205-213. PMID: 25344522. **IF: 5.814. (JCR 2014)**. Times Cited: 4. Q1
25. RAYA JM, MARTÍN-SANTOS T, LUÑO E, SANZO C, PEREZ-SIRVENT ML, SUCH E, NAVARRO JT, MILLÁ F, ALONSO E, DOMINGO A, ROZMAN M, DÍAZ-BEVA M, BATLLE A, GONZÁLEZ-DEVILLAMBROSIA S, TUSET E, VALLESPÍ T, ORTEGA M, BERMEJO A, MARTÍN-RAMOS M, PERI V, **SOLÉ F**, FLORENSA L. On behalf of the Grupo Español de Citología Hematológica (GECH), Working Group into the Sociedad Española de Hematología y Hemoterapia (SEHH). Acute myeloid leukemia with inv (3)(q21q26.2) or t(3;3)(q21;q26.2): clinical and biological features and comparison with other acute myeloid leukemias with cytogenetic aberrations involving long arm of chromosome 3. *Hematology* 2015 Feb 13. PMID: 25680074. **IF: 1.253. (JCR 2014)**. Times Cited: 0. Q4

26. **ADEMA V**, LARRÁYOZ MJ, CALASANZ MJ, PALOMO L, PATIÑO A, AGUIRRE X, HERNANDEZ JM, LUMBRERAS E, BUÑO I, MARTINEZ-LAPERCHE C, GARCÍA O, ALVAREZ S, BLAZQUEZ B, CERVERA J, LUÑO E, VALIENTE A, VALLESPÍ MT, VICENTE A, MALLO M, ARENILLAS L, COLLADO R, PEREZ-TEYZA J, **SOLÉ F**. Prognostic implications of the involvement of TP53 and SETBP1 in myelodysplastic syndromes with i(17)(q10). *British Journal of Haematology* 2015. PMID: 25716545. **IF. 4.979. (JCR 2014)**. Times Cited: 0. Q1
27. DELLA PORTA M, TUECHLER H, MALCOVATI L, SCHANZ J, SANZ G, GARCIA-MANERO G, **SOLÉ F**, BENNETT JM, BOWEN D, FENAUX P, DREYFUS F, KANTARJIAN K, KUENDGEN A, LEVIS A, CERMAK J, FONATSCH CH, LE BEAU MM, SLOVAK ML, KRIEGER O, LUEBBERT M, MACIEJEWSKI J, MAGALHAES SSM, YASUSHI MIYAZAKI, PFEILSTÖCKER M, SEKERES M, SPERR WR, STAUDER R, TAURO S, VALENT P, VALLESPI T, VAN DE LOOSDRECHT AA, GERMING U, HAASE D, GREENBERG PL, CAZZOLA M. Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM). *Leukemia* 2015. PMID. 25721895. **FI. 10,431. (JCR 2014)**. Times Cited: 2. Q1
28. SÁNCHEZ-CASTRO J, BETÉS VM, GÓMEZ-ARBONÉS X, GARCÍA-CERECEDO T, LÓPEZ R, TALAVERA E, FERNÁNDEZ S, ADEMÀ V, MARUGAN I, LUÑO E, SANZO C, VALLESPÍ T, ARENILLAS L, MARCO BUADES J, BATLLE A, BUEÑO I, MARTÍN RAMOS ML, BLÁZQUEZ RIOS B, COLLADO NIETO R, VARGAS MT, GONZÁLEZ MARTÍNEZ T, SANZ GF, **SOLÉ F**. Fluorescence in situ hybridization (FISH) of TP53 for the detection of chromosome 17 abnormalities in myelodysplastic syndromes. *Leuk Lymphoma* 2015; 10:1-13. PMID: 25754580. **IF. 2.891. (JCR 2014)**. Times Cited: 0. Q2
29. MCGRAW K, ZHANG LM, ROLLISON DE, BASIORKA AA, FULP W, JEREZ A, BILLINGSLEY BL, LIN HY, KURTIN SE, YODER S, ZHANG Y, GUINTEA K, MALLO M, SOLÉ F, CALASANZ MJ, CERVERA J, SUCH E, GONZÁLEZ T, SUNG S, NEVILL TJ, HAFERLACH T, MUFTI G, KARSAN A, MACIEJEWSKI JP, SOKOL L, EPLING-BURNETTE PK, WEI S, LIST AF. The Relationship of TP53 R72P Polymorphism to Disease Outcome and TP53 Mutation in del (5q) Myelodysplastic Syndromes. *Blood Cancer Journal* 2015. PMID: 25768405. **IF. 3,467. (JCR 2014)**. Times Cited: 1. Q2
30. CASTILLO JJ, BOWER M, BRÜHLMANN J, NOVAK U, FURRER H, TANAKA PY, BESSON C, MONTOTO S, Cwynarski K, ABRAMSON JS, DALIA S, BIBAS M, CONNORS JM, FURMAN M, NGUYEN ML, COOLEY TP, BELTRAN BE, COLLINS JA, VOSE JM, **XICOY B, RIBERA JM**; for the HIV-Associated Hodgkin Lymphoma in the CART Era Study Group. Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: A multi-institutional retrospective study. *Cancer* 2015; 121(3):423-31. **IF. 5,068. (JCR 2014)**. Times Cited: 1. Q1
31. TOPP M, GÖKBUGET N, STEIN AS, ZUGMAIER G, O'BRIEN S, BARGOU RC, DOMBRET H, FIELDING AK, HEFFNER L, LARSON RA, NEUMANN S; FOÀ R, LITZOW M, **RIBERA JM**, RAMBALDI A, SCHILLER G, BRÜGGEMANN M, HORST HA, HOLLAND C, JIA C, MANIAR T, HUBER B, NAGORSEN D, FORMAN SJ, KANTARJIAN HM. Immunotherapy with CD19-targeting Bispecific T-Cell Engager Blinatumomab in Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukaemia"Immunotherapy with CD19-targeting Bispecific T-Cell Engager Blinatumomab in Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia". *Lancet Oncology* 2015; 16: 57-66. **IF. 24,698. (JCR 2014)**. Times Cited: 41. Q1

32. **SORIGUE M, JUNCÀ J, SANCHO JM, MORGADES M, ESTEBAN D, NAVARRO JT, VIVES S, FELIU E, RIBERA JM.** Flow Cytometry for the Detection of Central Nervous System Disease in Acute Myeloblastic Leukemia. *Leuk Lymphoma* 2015 Feb 2:1-8. PubMed PMID: 25641427. **IF. 2,891 (JCR 2014).** Times Cited: 0. Q2
33. **VIVES S, ORIOL A, PIERNAS S, BRUNET S, CLAPÉS V, GUARDIA R, SUBIRÀ M, SIERRA J, RIBERA JM;** on behalf of the CETLAM Group. Feasibility and efficacy of outpatient therapy with intermediate dose cytarabine, fludarabine and idarubicin for patients with acute myeloid leukemia aged 70 or older. *Eur J Hematol* 2015 Feb 17. doi: 10.1111/ejh.12538. **I.F. 2,066. (JCR 2014).** Times Cited: 0. Q3
34. **BAPTISTA MJ, GARCIA O, MORGADES M, GONZALEZ-BARCA E, MIRALLES P, LOPEZ-GUILLERMO A, ABELLA E, MORENO M, SANCHO JM, FELIU E, RIBERA JM, NAVARRO JT.** HIV-infection impact on clinical-biological features and outcome of diffuse large B-cell lymphoma treated with R-CHOP in the combination antiretroviral therapy era. *AIDS* 2015; 29(7):811-8. **IF. 5,554. (JCR 2014).** Times Cited: 0. Q1
35. BARBA P, MARTINO R, MARTINEZ-CUADRON D, OLGA G, ESQUIROL A, GIL-CORTÉS C, GONZALEZ J, FERNANDEZ-AVILÉS F, VALCÁRCEL D, GUARDIA R, DUARTE RF, HERNANDEZ-RIVAS JM, ABELLA E, MONTESINOS P, **RIBERA JM.** Impact of transplant eligibility and the availability of an HLA-identical matched related donor on the outcome of older patients with acute lymphoblastic leukemia. *Leuk Lymphoma* 2015 Feb 17:1-16. PubMed PMID: 25686647. **IF. 2,891. (JCR 2014).** Times Cited: 1. Q2
36. BARTA SK, SAMUEL MS, XUE X, WANG D, LEE JY, MOUNIER N, **RIBERA JM, SPINA M, TIRELLI U, WEISS R, GALICIER L, BOUE F, LITTLE RF, DUNLEAVY K, WILSON WH, WYEN C, REMICK SC, KAPLAN LD, RATNER L, NOY A, SPARANO JA.** Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphoma. *Ann Oncol* 2015; 26(5):958-66. **IF. 7,04. (JCR 2014).** Times Cited: 2. Q1
37. TAPIA G, MD, **BAPTISTA MJ, MUÑOZ-MARMOL AM, GAAFAR A, PUENTE-POMPOSOM, GARCIA O, MARGINET-FLINCH R, SAN C, NAVARRO JT, SANCHO JM, RIBERA JM, ARIZA A, MATE JL.** MYC protein expression is associated with poor prognosis in primary diffuse large B-cell lymphoma of the central nervous system. *APMIS* 2015 Jul;123(7):596-603. **IF. 2,042. (JCR 2014).** Times Cited: 1. Q2
38. BERNAL T, MARTÍNEZ-CAMBLOR P, SÁNCHEZ-GARCÍA J, DE PAZ R, LUÑO E, NOMDEDEU B, ARDANAZ MT, PEDRO C, AMIGO ML, **XICOY B, DEL CAÑIZO C, TORMO M, BARGAY J, VALCÁRCEL D, BRUNET S, BENLLOCH L, SANZ G.** Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry. *Leukemia* 2015 May 6. doi: 10.1038/leu.2015.115. PubMed PMID: 25943181. **IF. 10,431. (JCR 2014).** Times Cited: 1. Q1
39. **ZAMORA L, XICOY B, CABEZÓN M, FERNANDEZ C, MARCÉ S, VELEZ P, XANDRI M, GALLARDO D, MILLÁ F, FELIU E, BOQUÉ C.** Co-existence of JAK2 V617F and CALR mutations in primary myelofibrosis. *Leuk Lymphoma* 2015 Mar 11:1-2. PubMed PMID: 25686645. **IF. 2,891. (JCR 2014).** Times Cited: 0. Q2
40. NIEMEYER CM, LOH ML, CSEH A, COOPER T, DVORAK CC, CHAN R, **XICOY B, GERMING U, KOJIMA S, MANABE A, DWORZAK M, DE MOERLOOSE B, STARÝ J, SMITH OP, MASETTI R, CATALA A, BERGSTRAESSER E, USSOWICZ M, FABRI O, BARUCHEL A, CAVÉ H, ZWAAN M, LOCATELLI F, HASLE H, VAN DEN HEUVEL-EIBRINK MM, FLOTHO C, YOSHIMI A.** Criteria for

evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemia. *Haematologica* 2015; 100(1):17-22. **IF. 5,814. (JCR 2014)**. Times Cited: 3. Q1

41. **ZAMORA L**, GERMING U, CABEZÓN M, SCHULER E, ARNAN M, MARCÉ S, COLL R, POMARES H, BRINGS C, PALOMO L, SCHMENEAU J, GALLARDO D, **MILLÁ F**, **FELIU E**, **XICOY B**. Calreticulin mutations are not present in patients with myeloproliferative chronic myelomonocytic leukemia. *Ann Hematol* 2015; 94(5):869-71. **IF. 2,634. (JCR 2014)**. Times Cited: 0. Q2
42. **SORIGUÉ M**, **XICOY B**, GRIFOLS JR, **RIBERA JM**. [Autoimmune hemolytic anemia refractory to medical treatment after chlorine dioxide intake in a patient with idiopathic thrombocytopenic purpura]. *Med Clin (Barc)* 2015; 144(7):332-3. **IF. 1,417. (JCR 2014)**. Times Cited: 0. Q2
43. **FERRÀ C**, SANZ J, DÍAZ-PÉREZ MA, **MORGADES M**, GAYOSO J, CABRERA JR, VILLAESCUSA T, SAMPOL MA, FERNÁNDEZ-AVILÉS F, SOLANO C, ORTÍN M, DUARTE R, CUESTA M, HERAS I, DE LA SERNA J, MORALEDA JM, BARRENETXEA C, GONZÁLEZ-VICENT M, SANZ G, **RIBERA JM**; Grupo Español de Trasplante Hematopoyético (Geth) Spanish Society of Hematology. Outcome of graft failure after allogeneic stem cell transplant: study of 89 patients. *Leuk Lymphoma* 2015; 56: 656-62. **IF. 2,891. (JCR 2014)**. Times Cited: 0. Q2
44. STEWART AK, RAJKUMAR SV, DIMOPOULOS MA, MASSZI T, ŠPIČKA I, **ORIOLO A**, HÁJEK R, ROSIÑOL L, SIEGEL DS, MIHAYLOV GG, GORANOVA-MARINOVA V, RAJNICS P, SUVOROV A, IESVIZKY R, JAKUBOWIAK AJ, SAN-MIGUEL JF, LUDWIG H, WANG M, MAISNAR V, MINARIK J, BENSINGER WI, MATEOS MV, BEN-YEHUDA D, KUKRETI V, ZOJWALLA N, TONDA ME, YANG X, XING B, MOREAU P, PALUMBO A; ASPIRE Investigators. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. *N Engl J Med* 2015; 372(2):142-52. **IF. 55,873. (JCR 2014)**. Times Cited: 34. Q1
45. **ORIOLO A**. Treatment of relapsed or refractory acute lymphoblastic leukemia in adult patients. *Acta Haematol* 2015;133(1):89-90. **IF.1,116. (JCR 2014)**. Times Cited: 0. Q4
46. **SANCHO JM**, **GARCÍA O**, MERCADAL S, POMARES H, FERNÁNDEZ-ALVAREZ R, GONZÁLEZ-BARCA E, TAPIA G, GONZÁLEZ-GARCÍA E, **MORENO M**, DOMINGO-DOMÈNECH E, SORIGUÉ M, **NAVARRO JT**, MOTLLÓ C, FERNÁNDEZ-DE-SEVILLA A, **FELIU E**, **RIBERA JM**. The long term follow-up of early stage follicular lymphoma treated with radiotherapy, chemotherapy or combined modality treatment. *Leukemia Research* 2015; 39: 853-858. **IF. 2,351. (JCR 2014)**. Times Cited: 0. Q3
47. BRITOS-FRANCO P, RODRÍGUEZ-HERNÁNDEZ I, **NAVARRO JT**, **GRANADA I**, TAPIA G, **JUNCÀ J**, **RIBERA JM**, **MILLÁ F**. Translocation (18;22)(q21;q11.2) in B-cell lymphoproliferative disorders: a report of six cases. *Leuk Lymphoma* 2015 Mar;56(3):789-92. doi: 10.3109/10428194.2014.928932... **IF. 2,891 (JCR 2014)**. Times Cited: 0. Q2
48. **MARCÉ S**, CORTÉS M, **ZAMORA L**, **CABEZÓN M**, **GRAU J**, **MILLÁ F**, **FELIU E**. A Thirty-five Nucleotides BCR-ABL1 Insertion Mutation of Controversial Significance Confers Resistance to Imatinib in a Patient with Chronic Myeloid Leukemia (CML). *Exp Mol Pathol* 2015 Apr 22; 99(1):16-18. **IF. 2,706. (JCR 2014)**. Times Cited: 0. Q2
49. **RIBERA J**, **MORGADES M**, **ZAMORA L**, MONTESINOS P, GÓMEZ I, PRATCORONA M, SARRA J, GUARDIA R, NOMDEDEU J, TORMO M, MARTI J, HENÁNDEZ RIVAS JM, GONZÁLEZ S, BARBA P, ESCODA L, **GENESCÀ E**, **SOLÉ F**, **MILLÁ F**, **FELIU E**, **RIBERA JM**. Prognostic significance of copy number alterations in adolescent and adult patients with precursor B acute lymphoblastic leukemia enrolled in PETHEMA protocols. *Cancer* 2015. **IF. 5,068 (JCR 2014)**. Times Cited: 0. Q1

50. SAUMELL S, **SOLÉ F**, ARENILLAS L, MONTORO J, VALCÁRCEL D, PEDRO C, SANZO C, LUÑO E, GIMÉNEZ T, ARNAN M, POMARES H, DE PAZ R, ARRIZABALAGA B, JEREZ A, MARTÍNEZ AB, SÁNCHEZ-CASTRO J, RODRÍGUEZ JD, RAYA JM, RÍOS E, RODRÍGUEZ-RIVERA M, ESPINET B, FLORENSA L. Trisomy 8 in de novo myelodysplastic syndrome. Constitutional or not constitutional. Plos One. 12;10(6):e0129375. PMID: 26066831. **FI. 3,234. (JCR 2014)**. Times Cited: 0. Q1
51. BRAULKE F, MÜLLER-THOMAS C, GÖTZE K, PLATZBECKER U, GERMING U, HOFMANN WK, GIAGOUNIDIS A, LÜBBERT M, . GREENBERG PL, BENNETT J **SOLÉ F**, SLOVAK ML, OHYASHIKI K, LE BEAU MM, TÜCHLER H, PFEILSTÖCKER M, HILDEBRANDT B, AUL C, STAUDER R, VALENT P, FONATSCH CH, BACHER U, TRÜMPER L, HAASE DM, SCHANZ J. Results from a German diagnostic study in comparison with an international control group reveals that the frequency of del(12p) is commonly underestimated in Myelodysplastic Syndromes. Genes Chromosomes and Cancer. Genes 2015 Sep 10. doi: 10.1002/gcc.22292. PMID: 26355708. **FI. 4,041. (JCR 2014)**. Times Cited: 0. Q1
52. MCGRAW K, CLUZEAU T*, SALLMAN DA, BASIORKA AA, IRVINE BA, ZHANG L, BURNETTE E, ROLLISON DE, **MALLO M**, SOKOL L, **SOLÉ F**, MACIEJEWSKI J, LIST AF: TP53 and MDM2 single nucleotide polymorphisms influence survival in non-del(5q) myelodysplastic syndromes. Oncotarget. PMID: 26416416. **FI. 6,359. (JCR 2014)**. Times Cited: 0. Q1
53. **RIBERA JM**. Leukaemic vasculitis from myelodysplastic syndrome in context. Lancet. 2015; 386(9992):502. **IF. 45,217. (JCR 2014)**. Times Cited: 0. Q1
54. SPINA M, NAGY Z, **RIBERA JM**, FEDERICO M, AURER I, JORDAN K, BORSARU G, PRISTUPA AS, BOSI A, GROSICKI S, GLUSHKO NL, RISTIC D, JAKUCS J, MONTESINOS P, MAYER J, REGO EM, BALDINI S, SCARTONI S, CAPRIATI A, MAGGI CA, SIMONELLI C; FLORENCE Study Group. FLORENCE: a randomized, double-blind, phase III pivotal study of febusostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk. Ann Oncol. 2015;26(10):2155-61. **IF. 7,04. (JCR 2014)**. Times Cited: 0. Q1
55. PANTANO L, JODAR M, BAK M, BALLESCÀ JL, TOMMERUP N, OLIVA R, **VAVOURI T**. The small RNA content of human sperm reveals pseudogene-derived piRNAs complementary to protein-coding genes. RNA 2015 Jun;21(6):1085-95. doi: 10.1261/rna.046482.114. PMID: 25904136. **IF. 4,936. (JCR 2014)**. Times Cited: 1 Q1
56. **SORIGUE M**, **JUNCA J**, **GRANADA I**. CD200 in High-Grade Lymphoma, Chronic Lymphocytic Leukemia, and Chronic Lymphocytic Leukemia-Phenotype Monoclonal B-Cell Lymphocytosis. Am J Clin Pathol. 2015 Oct; 144(4):677-9. doi: 10.1309/AJCPO2KKFH0EXNZF.. PMID: 26386092.. **IF.2,514. (JCR 2014)**. Times Cited: 0 Q2
57. **RUIZ-XIVILLÉ N**, **GRANADA I**, **CAMPOS D**, **CISNEROS A**, **GRAU J**, **XANDRI M**, **ARNAN M**, **LLOVERAS N**, **ESCODA L**, **FONT L**, **MILLÁ F**, **RIBERA JM**. Clinical usefulness of fluorescence in situ hybridization for detection of MLL rearrangements in acute myeloid leukemia. Leuk Lymphoma. 2015 Feb 20:1-3. PMID: 25549805. Similar articles. Select item 25116331. **IF. 2,891. (JCR 2014)**. Times Cited: 0 Q2
58. **RIBERA JM**, **FERRER A**, **RIBERA J**, **GENESCÀ E**. Profile of blinatumomab and its potential in the treatment of relapsed/refractory acute lymphoblastic leukemia. Onco Targets Ther. 2015 Jun 24; 8:1567-74. doi: 10.2147/OTT.S70524. eCollection 2015. **IF: 2,351. (JCR 2014)**. Times Cited: 1 Q2

59. **GENESCÀ E, RIBERA J, RIBERA JM.** Acute lymphoblastic leukemia of T progenitors from biology to clinics. *Med Clin (Barc)* 2015 Mar 9; 144(5): 223-9. Doi 10.1016 **IF: 1,417. (JCR 2014).** Times Cited: 0. Q2
60. SORIGUÉ M, **JUNCÀ J, GASSIOT S, MILLÀ F, MATE JL, NAVARRO JT.** A case of CD138-/CD19+/CD4+ IgD plasma cell leukemia. *Cytometry Part B (Clinical Cytometry)* 2015; 88: 69-73. **IF: 2.398. (JCR 2014).** Times Cited: 0. Q2
61. GARCÍA-SANZ R, **ORIOI A, MORENO MJ, DE LA RUBIA J, PAYER AR, HERNÁNDEZ MT, PALOMERA L, TERUEL AI, BLANCHARD MJ, GIRONELLA M, RIBAS P, BARGAY J, ABELLÀ E, GRANELL M, OCIO EM, RIBERA JM, SAN MIGUEL JF, MATEOS MV;** Spanish Myeloma Group (GEM/PETHEMA). Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial. *Haematologica.* 2015; 100(9):1207-13. **IF: 5,814. (JCR 2014).** Times Cited: 0. Q1
62. **ORIOI A, GIRALDO P, KOTSIANIDIS I, COUTURIER C, OLIE R, ANGERMUND R, CORSO A.** Efficacy and safety of bortezomib-based retreatment at the first relapse in multiple myeloma patients: A retrospective study. *Hematology.* 2015; 20(7):405-9. **IF: 1,253. (JCR 2014).** Times Cited: 0. Q4
63. FERNÁNDEZ-ALVAREZ R, GONZÁLEZ-RODRIGUEZ AP, GONZALEZ ME, RUBIO-CASTRO A, DOMINGUEZ-IGLESIAS F, SOLANO J, ALONSO-NOGUES E, FERNANDEZ-ALVAREZ C, ZANABILI Y, ALONSO JM, PAYER AR, VICENTE JM, MEDINA J, **SANCHO JM.** Serum ferritin as prognostic marker in classical Hodgkin lymphoma treated with ABVD-based therapy. *Leuk Lymphoma.* 2015; 56:3096-102. **IF: 2,891. (JCR 2014).** Times Cited: 0. Q2
64. CASTILLO N, GARCÍA-CADENAS I, GARCÍA O, BARBA P, HEREDIA CD, **MARTINO R, AZQUETA C, FERRÀ C, CANALS C, ELORZA I, OLIVÉ T, BADELL I, SIERRA J, DUARTE R, VALCÁRCEL D, QUEROL S.** Few and Nonsevere Adverse Infusion Events Using an Automated Method for Diluting and Washing before Unrelated Single Cord Blood Transplantation. *Biol Blood Marrow Transplant.* 2015; 21: 682-687. **IF: 3.404. (JCR 2014).** Times Cited: 0. Q2
65. GARCÍA-CADENAS I, CASTILLO N, **MARTINO R, BARBA P, ESQUIROL A, NOVELLI S, ORTI G, GARRIDO A, SAAVEDRA S, MORENO C, GRANELL M, BRIONES J, BRUNET S, NAVARRO F, RUIZ I, RABELLA N, VALCÁRCEL D, SIERRA J.** Impact of Epstein Barr virus-related complications after high-risk allo-SCT in the era of pre-emptive rituximab. *Bone Marrow Transplant* 2015 Jan 12. doi: 10.1038/bmt.2014.298. PubMed PMID: 25581404. **IF: 3.578. (JCR 2014).** Times Cited: 0. Q2
66. **MARTINO R, BAUTISTA G, PARODY R, GARCÍA I, ESQUIROL A, ROVIRA M, CABRERA JR, REGIDOR C, FORÉS R, GARCÍA-MARCO JA, SERRANO D, BARBA P, HERAS I, MARQUEZ-MALAVÉ FJ, SÁNCHEZ-ORTEGA I, DUARTE R, SAAVEDRA S, VAZQUEZ L;** The Infectious/Non-infectious Complications Subcommittee of the Grupo Español de Trasplante Hematopoyético (GETH). Severe infections after single umbilical cord blood transplantation in adults with or without the co-infusion of CD34(+) cells from a third-party donor: results of a multicenter study from the Grupo Español de Trasplante Hematopoyético (GETH). *Transpl Infect Dis* 2015 Feb 3. doi: 10.1111/tid.12361. PubMed PMID: 25652036. **IF: 2.064. (JCR 2014).** Times Cited: 0. Q3
67. MORENO MJ, BOSCH R, DIEGUEZ-GONZALEZ R, NOVELLI S, MOZOS A, GALLARDO A, PAVÓN MÁ, CÉSPEDES MV, GRAÑENA A, ALCOCEBA M, BLANCO O, GONZALEZ-DÍAZ M, **SIERRA J, MANGUES R, CASANOVA I.** CXCR4 expression enhances diffuse large B cell lymphoma dissemination and decreases patient survival. *J Pathol* 2015 Feb;235(3):445-55. doi:

10.1002/path.4446. Epub 2014 Dec 11. PubMed PMID: 25231113. **IF. 7.420. (JCR 2014)**. Times Cited: 3. Q1

68. RUGGERI A, LABOPIN M, SANZ G, PIEMONTESE S, ARCESE W, BACIGALUPO A, BLAISE D, BOSI A, HUANG H, KARAKASIS D, KOC Y, MICHALLET M, PICARDI A, SANZ J, SANTARONE S, SENGELOV H, **SIERRA J**, VINCENT L, VOLT F, NAGLER A, GLUCKMAN E, CICERI F, ROCHA V, MOHTY M. Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia. *Leukemia* 2015 Apr 17. doi: 10.1038/leu.2015.98. PubMed PMID: 25882700. **IF. 10,431. (JCR 2014)**. Times Cited: 6. Q1
69. DE LA TORRE C, CASANOVA I, ACOSTA G, COLL C, **MORENO MJ**, ALBERICIO F, AZNAR E, **MANGUES R**, ROYO M, SANCENÓN F, MARTÍNEZ-MÁÑEZ R. Gated Mesoporous Silica Nanoparticles Using a Double-Role Circular Peptide for the Controlled and Target-Preferential Release of Doxorubicin in CXCR4-expressing Lymphoma cells. *Adv Funct Mater* 2015, 25(5):687–695, DOI: 10.1002/adfm.201403822. **IF: 11.805. (JCR 2014)**. Times Cited: 1. Q1
70. CASTILLO N, GARCÍA-CADENAS I, BARBA P, MARTINO R, AZQUETA C, FERRÀ C, CANALS C, SIERRA J, VALCÁRCEL D, QUEROL S. POST-THAW VIABLE CD45(+) Cells and Clonogenic Efficiency are Associated with Better Engraftment and Outcomes after Single Cord Blood Transplantation in Adult Patients with Malignant Diseases. *BIOL BLOOD MARROW TRANSPLANT*. 2015; 12: 2167-72. **IF: 3,404. (JCR 2014)**. Times Cited: 0. Q2
71. BARON F, LABOPIN M, RUGGERI A, MOHTY M, SANZ G, MILPIED N, BACIGALUPO A, RAMBALDI A, BONIFAZI F, BOSI A, **SIERRA J**, YAKOUB-AGHA I, **SANTASUSANA JMR**, GLUCKMAN E, NAGLER A. Unrelated cord blood transplantation for adult patients with acute myeloid leukemia: higher incidence of acute graft-versus-host disease and lower survival in male patients transplanted with female unrelated cord blood—a report from Eurocord, the Acute Leukemia Working Party, and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the European Group for Blood and Marrow Transplantation. *JOURNAL OF HEMATOLOGY & ONCOLOGY*. OCT 2015; 8; 107; DOI: 10.1186/S13045-015-0207-4. **IF. 4,812. (JCR 2014)**. Times Cited: 0. Q1
72. VALCARCEL, DAVID; SANZ, GUILLERMO; ORTEGA, MARGARITA; NOMDEDEU, BENET; LUNO, ELISA; DIEZ-CAMPELO, MARIA; TERESA ARDANAZ, MARIA; PEDRO, CARMEN; MONTORO, JULIA; COLLADO, ROSA; ANDREU, RAFA; MARCO, VICTOR; TERESA CEDENA, MARIA; DE PAZ, RAQUEL; TORMO, MAR; **XICOY, BLANCA**; RAMOS, FERNANDO; BARGAY, JOAN; GONZALEZ, BERNARDO; BRUNET, SALUT; ANTONIO MUNOZ, JUAN; GOMEZ, VALLE; BAILEN, ALICIA; SANCHEZ, JOAQUIN; MERCHAN, BRAYAN; DEL CANIZO, CONSUELO; VALLESPI, TERESA. Use of newer prognostic indices for patients with myelodysplastic syndromes in the low and intermediate-1 risk categories: a population-based study. *LANCET HAEMATOLOGY*. 2015; 2; 6; E260, E266 (**JCR 2014**). Times Cited: 1. Q1
73. **RIBERA, JOSEP-MARIA; FERRER, ALBERT; RIBERA, JORDI; GENESCA, EULALIA**. Profile of blinatumomab and its potential in the treatment of relapsed/refractory acute lymphoblastic leukemia. *ONCOTARGETS AND THERAPY*. 2015; 8; 1567-1574. 10.2147/OTT.S70524 **IF: 2,311 (JCR 2014)**. Times Cited: 1. Q2
74. AKIL, AYMAN; ZHANG, QING; MUMAW, CHRISTEN L.; RAIKER, NISHA; YU, JEFFREY; DE MENDIZABAL, NIEVES VELEZ; HANELINE, LAURA S.; ROBERTSON, KENT A.; SKILES, JODI; DIAZ-RICART, MARIBEL; **CARRERAS, ENRIC**; RENBARGER, JAMIE; HANASH, SAMIR; BIES, ROBERT R.; PACZESNY, SOPHIE. Biomarkers for Diagnosis and Prognosis of Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation. *BIOLOGY OF BLOOD AND MARROW*

75. KYLE J GAULTON, TERESA FERREIRA, YEJI LEE, ANNE RAIMONDO, REEDIK MÄGI, MICHAEL E RESCHEN, ANUBHA MAHAJAN, ADAM LOCKE, N WILLIAM RAYNER, NEIL ROBERTSON, ROBERT A SCOTT, INGA PROKOPENKO, LAURA J SCOTT, TODD GREEN, THOMAS SPARSO, DOROTHEE THUILLIER LOIC YENGO, HARALD GRALLERT, SIMONE WAHL, MATTIAS FRÅNBERG, RONA J STRAWBRIDGE, HANS KESTLER, HIMANSHU CHHEDA, LEWIN EISELE, STEFAN GUSTAFSSON, VALGERDUR STEINTHORSDDOTTIR, GUDMAR THORLEIFSSON, LU QI, LENNART C KARSSON, ELISABETH M VAN LEEUWEN, SARA M WILLEMS, MAN LI, HAN CHEN, CHRISTIAN FUCHSBERGER, PHOENIX KWAN, CLEMENT MA, MICHAEL LINDERMAN, YINGCHANG LU, SOREN K THOMSEN, JANA K RUNDLE, NICOLA L BEER, MARTIJN VAN DE BUNT, ANIL CHALISEY, HYUN MIN KANG, BENJAMIN F VOIGHT, GONCALO R ABECASIS, PETER ALMGREN, DAMIANO BALDASSARRE, BEVERLEY BALKAU, RAFN BENEDIKTSSON, MATTHIAS BLÜHER, HEINER BOEING, LORI L BONNYCASTLE, ERWIN P BORRINGER, NOËL P BURTT, JASON CAREY, GUILLAUME CHARPENTIER, PETER S CHINES, MARILYN C CORNELIS, DAVID J COUPER, ANDREW T CRENSHAW, ROB M VAN DAM, ALEX SF DONEY, MOZHGAN DORKHAN, SARAH EDKINS, JOHAN G ERIKSSON, TONU ESKO, ELODIE EURY, JOÃO FADISTA, JASON FLANNICK, PIERRE FONTANILLAS, CAROLINE FOX, PAUL W FRANKS, KARL GERTOW, CHRISTIAN GIEGER, BRUNA GIGANTE, OMRI GOTTESMAN, GEORGE B GRANT, NIELS GRARUP, CHRISTOPHER J GROVES, MAIJA HASSINEN, CHRISTIAN T HAVE 11 , CHRISTIAN HERDER, ODDGEIR L HOLMEN, ASTRADUR B HREIDARSSON, STEVE E HUMPHRIES, DAVID J HUNTER, ANNE U JACKSON, ANNA JONSSON, MARIT E JØRGENSEN, TORBEN JØRGENSEN, WEN-HONG L KAO, NICOLA D KERRISON, LEENA KINNUNEN, NORMAN KLOPP, AUGUSTINE KONG, PETER KOVACS, PETER KRAFT, JASMINA KRAVIC, CORDELIA LANGFORD, KARIN LEANDER, LIMING LIANG, PETER LICHTNER, CECILIA M LINDGREN, EERO LINDHOLM, ALLAN LINNEBERG, CHING-TI LIU, STÉPHANE LOBBENS, JIAN'AN LUAN, VALERIYA LYSSSENKO, SATU MÄNNISTÖ, OLGA MCLEOD, JULIA MEYER, EVELIN MIHAILOV, GHAZALA MIRZA, THOMAS W MÜHLEISEN, MARTINA MÜLLER-NURASYID, CARMEN NAVARRO, MARKUS M NÖTHEN, NIKOLAY N OSKOLKOV, KATHARINE R OWEN, DOMENICO PALLI, SONALI PECHLIVANIS, LEENA PELTONEN, JOHN RB PERRY, CARL GP PLATOU, MICHAEL RODEN, DOUGLAS RUDERFER, DENIS RYBIN, YVONNE T VAN DER SCHOUW, BENGT SENNBLAD, GUNNAR SIGURÐSSON, ALENA STANČÁKOVÁ, GERALD STEINBACH, PETTER STORM, KONSTANTIN STRAUCH, HEATHER M STRINGHAM, QI SUN, BARBARA THORAND, EMMI TIKKANEN, ANKE TONJES, JOSEPH TRAKALO, ELENA TREMOLI, TIINAMAIIJA TUOMI, ROMAN WENNAUER, STEVEN WILTSHIRE, ANDREW R WOOD, ELEFThERIA ZEGGINI, IAN DUNHAM, EWAN BIRNEY, **LORENZO PASQUALI**, JORGE FERRER, RUTH JF LOOS, JOSÉE DUPUIS, JOSE C FLOREZ, ERIC BOERWINKLE, JAMES S PANKOW, CORNELIA VAN DUIJN, ERIC SIJBRANDS, JAMES B MEIGS, FRANK B HU, UNNUR THORSTEINSDOTTIR, KARI STEFANSSON, TIMO A LAKKA, RAINER RAURAMAA, MICHAEL STUMVOLL, NANCY L PEDERSEN, LARS LIND, SIRKKA M KEINANEN- KIUKAANNIEMI, EEVA KORPIHYÖVÄLTI, TIMO E SAARISTO, JUHA SALTEVO, JOHANNA KUUSISTO, MARKKU LAAKSO, ANDRES METSPALU, RAIMUND ERBEL, KARL-HEINZ JÖCKEL, SUSANNE MOEBUS, SAMULI RIPATTI, VEIKKO SALOMAA, ERIK INGELSSON, BERNHARD OBOEHM, RICHARD N BERGMAN, FRANCIS S COLLINS, KAREN L MOHLKE, HEIKKI KOISTINEN, JAAKKO TUOMILEHTO, KRISTIAN HVEEM, INGER NJØLSTAD, PANAGIOTIS DELOUKAS, PETER J DONNELLY, TIMOTHY M FRAYLING, ANDREW T HATTERSLEY, ULF DE FAIRE, ANDERS HAMSTEN, THOMAS ILLIG, ANNETTE PETERS, STEPHANE CAUCHI, ROB SLADEK, PHILIPPE FROGUEL, TORBEN HANSEN, OLUF PEDERSEN, ANDREW D MORRIS, COLLIN NA PALMER, SEKAR KATHIRESAN, OLLE MELANDER, PETER M NILSSON, LEIF C GROOP, INÊS BARROSO, CLAUDIA LANGENBERG, NICHOLAS J WAREHAM, CHRISTOPHER A O'CALLAGHAN, ANNA L GLOYN, DAVID ALTSHULER, MICHAEL BOEHNKE, TANYA M TESLOVICH, MARK I MCCARTHY, ANDREW P MORRIS, for the DIABetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium. Genetic fine-mapping and genomic annotation defines causal

- mechanisms at type 2 diabetes susceptibility loci. *Nature Genetics*. 2015; 47; 12; 1415. 10.1038/ng.3437 . **IF: 29,352 (JCR 2014)**. Times Cited: 0. Q1
76. MIGUEL-ESCALADA I, **PASQUALI L**, FERRER J. Transcriptional enhancers: functional insights and role in human disease. *Curr Opin Genet Dev*. 2015 Sep 30;33:71-76. doi: 10.1016/j.gde.2015.08.009. **IF: 7,574 (JCR 2014)**. Times Cited: 0. Q1
77. **RIBERA, JOSEP-MARIA; VIVES, SUSANA; MOTLLO, CRISTINA; JIMENEZ-LORENZO, MARIA-JOSE**. Blinatumomab for treating acute lymphoblastic leukemia. *EXPERT OPINION ON ORPHAN DRUGS*. 2015; 3; 4; 477 – 485. 10.1517/21678707.2015.1024223. **IF: 0,529 (JCR 2014)**. Times Cited: 0. Q4
78. SAUMELL, SILVIA S; FLORENSA, LOURDES F; RODRIGUEZ-RIVERA, MARIA R; PEDRO, CARME P; MARIA HERNANDEZ-RIVAS, JESUS M; LUMBRERAS, EVA L; ABAIGAR, MARIA A; COLLADO, ROSA C; IVARS, DAVID I; CARBONELL, FELIX C; MARUGAN, ISABEL M; TOROMO, MAR T; BOTIA, MERCEDES B; ANGELES PINAN, MARIA A; ANCIN, IDOIA A; GONZALEZ, TERESA G; DIAZ VARELA, NICHOLAS D; GRAU, JAVIER G; GRANADA, ISABEL G; RUIZ, NEUS R; LUISA MARTIN, MARIA L; FERNANDEZ-GUIJARRO, MANUELA F; DUARTE, JOSE-JOAOQUIN D; JOSE CALASANZ, MARIA J; JOSE LARRAYOZ, MARIA J; **SOLE, FRANCESC**. Fluorescence in situ hybridization analysis does not increase detection rate for trisomy 8 in chronic myelomonocytic leukemia. 2015; *LEUKEMIA & LYMPHOMA* 56; 1; 242 – 243. 10.3109/10428194.2014.914197. **IF: 2,891 (JCR 2014)**. Times Cited: 0. Q2
79. NOMDEDEU, MERITXELL; CARMEN LARA-CASTILLO, MARIA; ETXABE, AMAIA; MARIA CORNET-MASANA, JOSEP; PRATCORONA, MARTA; DIAZ-BEYA, MARINA; CALVO, XAVIER; ROZMAN, MARIA; COSTA, DOLORS; ESTEVE, JORDI; **RISUENO, RUTH M**. Treatment with G-CSF reduces acute myeloid leukemia blast viability in the presence of bone marrow stroma. *CANCER CELL INTERNATIONAL*. 2015. 15; 122. 10.1186/s12935-015-0272-3 **IF: 2,766 (JCR 2014)**. Times Cited: 0. Q3.
80. OLIVEIRA, A. C.; FERNANDEZ DE SEVILLA, AF; DOMINGO, A.; DE LA BANDA, E.; DOMINGO-DOMENECH, E.;MERCADAL, S.; **RUIZ-XIVILLE, N.**;ALONSO, E.; ENCUESTRA, M.;GONZALEZ-BARCA, E. Prospective study of prognostic factors in asymptomatic patients with B-cell chronic lymphocytic leukemia-like lymphocytosis: the cut-off of 11 x 10⁹/L monoclonal lymphocytes better identifies subgroups with different outcomes. *ANNALS OF HEMATOLOGY*.2015. 94;4;627-632. DOI: 10.1007/s00277-014-2263-1. IF: 2,634 (JCR 2014). Times Cited: 1. Q2.